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SUMMARY 
The present work is a study of the structure-activity relation-
ships and mode of action of oestrogens substituted with alkylating 
functions. These compounds are cytotoxic agents potentially selective 
for oestrogen-responsive tumours, since the oestrogen part of the 
molecule should lead to a concentration in tumour cells thereby 
imparting selectivity to the alkylating group. 
An assay system was developed to test a series of compounds for 
the above properties. This system consisted of a cytotoxicity screen, 
using HeLa S3 cells, and a receptor binding assay using rat uterine 
cytosols to evaluate the compounds' selectivity. Selectivity was 
further assessed by use of the oestrogen-receptor containing cell 
lines MCF-7 and GH3' 
The devised system was used to evaluate a series of oestrogen 
D-ring a-methylene-o-lactones previously prepared in the Organic 
Chemistry Laboratory (Dr. L.S. Chagonda). Although strongly cytotoxic 
(ICso < luM against HeLa S3) these compounds show little affinity for 
the oestrogen receptor, and no apparent selectivity against MCF-7 and 
GH3 cells. This suggests that the 17-oxygen function is important 
for receptor binding, and modifications in this region of the oestrogen 
molecule result in loss of affinity for the receptor. 
Consequently oestrogens retaining the 17-oxygen, but substituted 
at the l6-position with an a-methylene-y-lactone ring were proposed. 
Three compounds of this type were prepared (Dr. G. Edge). These 
compounds are cytotoxic to HeLa S3 cells, though less so than the 
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D-ring ~-methylene-c-lactone oestrogens (ICSO < 5~M). Two of these 
compounds exhibit a degree of affinity for the oestrogen receptor, 
and one of these has greater cytotoxic activity against MCF-7 cells 
than would be predicted for non-oestrogen compounds. However, it has 
not been possible to confirm the work on this active compound as it 
has four possible isomers, which may vary in selecti vi ty. Work is 
presently underway to separate the isomers. 
Two epoxide isomers derived from ethinyl oestradiol (prepared by 
Miss J.C. Gill) were also assessed. Both of these compounds are 
cytotoxic to HeLa S3 cells (at ~ 10~M levels), one being threefold 
more active. The more cytotoxic isomer also displays high affinity 
for the oestrogen receptor with an EDso of approximately 70 nM, i.e. 
greater than that of oestrone (EDso ~ 100 nM). This series of compounds 
is potentially very interesting and well worth further study, particularly 
if more active cytotoxic groups could be incorporated. 
All of the alkylating oestrogen derivatives tested appear to 
form covalent links with the oestrogen receptor. The degree of 
·covalent binding is apparently a function of both binding affinity and 
reactivity. 
A study was also made of the possible mechanisms by which the 
compounds might block cell grOl,th. Particular attention was paid to 
the role of thiol groups. All of the active compounds reduce cellular 
thiols and react with glutathione to some extent. 
Thymidine uptake and incorporation into DNA, respiration, 
lysosomal enzymes and lysosomal membranes were examined. All of 
iii 
these parameters were affected to varying degrees. However, the 
a-methylene-lactone compounds were found to be most active against 
Na+/.K ATPase as determined by 86Rb+ uptake into HeLa S3 cells and 
by effects on isolated preparations of the enzyme. 
Abbreviations 
Chemicals and Reagents: 
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1. INTRODUCTION 
2 
1.1 Definitions of Cancer 
Cancer is described as an abnormal growth of tissue without 
the constraints that characterise normal tissue growth. [1] The 
rate of growth in malignant lesions is not necessarily higher than 
the tissues from which they originate. [1] However the feedback 
control mechanisms which govern tissue size do not operate on 
malignant neoplasms, they become at least partly autofiomous. [2] 
In general, malignant lesions can be distinguished from the benign 
form by several properties. [1,3] 
(a) Benign neoplasms tend to show some degree of differentiation 
and resemble the tissues from which they originate in organisation. 
Malignant neoplasms are relatively undifferentiated 
(b) Benign lesions commonly form a surrounding capsule and are 
distinct from the surrounding tissues while malignant lesions 
invade and destroy surrounding tissue. 
(c) Most importantly few benign lesions metastasise, while a common 
property of malignant neoplasms is an ability to form secondary 
lesions at sites distant from the primary. 
In addition to localised destruction of healthy tissues, 
malignant lesions have a general deleterious effect on metabolism, 
this is termed cachexia. [3,4] One of the earliest observations on 
cancer cells was their increased rate of glycolytic metabolism. 
The resultant accumulation of lact~tc and its release into the 
bloodstream by malignant lesions is partly responsible for the 
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'wasting' effect seen in cancer. Production of inappropriate 
gene products such as ectopic hormones, or toxic metabolites add 
to this metabolic disruption. 
From a clinical point of vie,., cancer is difficult to define 
in any useful sense. There are no absolute distinctions between 
malignant and benign neoplasms and only qualified generalisations 
can be made about their properties. [5] Cancer is better defined 
therefore in terms of its causes, and of the changes which occur at 
a cellular level which transform a normal cell to its neoplastic 
counterpart. 
4 
1.2 Causes of Cancer 
Cancer has a genetic basis. All known carcinogens; chemicals, 
radiation and viruses cause mutations which lead to the transformation 
of normal cells. [2] Recently it has been demonstrated that the 
target for these carcinogens are specific genes, termed oncogenes, 
found in normal cells. [6,7] Oncogenes code for normal cell 
proteins, usually enzymes, such as protein kinases, or gr0l1th 
factors, When forced into an abnormal 'rate of expression oncogenes 
overproduce these proteins and this may cause the cell to become 
neoplastic. [8,9] 
Chemical and radiation carcinogenesis occurs by mutation of a 
normal gene. [10] Point mutation of a single nucleotide base 
may be sufficient to convert a normal gene teo one which causes 
cancer. [7] Such a point mutation has been implicated in a form 
of bladder c~ncer caused by several carcinogens, [7]. A large number 
of organic and inorganic compounds have been shown to be carcinogenic 
or are suspected of being so, some examples of these are shown in 
Figure 1.1. 
Most of the organic chemical carcinogens undergo metabolic 
activation to an ultimate carcinogenic form which reacts with DNA. [7,10,11: 
This 'lethal synthesis' depends on the type of tissue and its 
metabolism, which may account for the specific carcinogenic activity 
of compounds on certain tissues. [10] For example vinyl chloride 
on the liver (angiosarcoma), and 2-napthylamine and benzidine on 
5 
3-Methylcholanthrene 
2-Aminonaphthalene 
Vinyl Chloride 
CJ N-Nitrosopiperidine 
I 
NO 
Ni(CO~ Nickel Carbonyl 
Figure 1.1. Compounds which are c~rcinogenic in humans 
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the bladder. [10,11] The carcinogenic activity of a compound on a 
tissue will depend partly on the relative levels of the enzymes 
which activate the compound and those which detoxify it, as well 
as the reactivity of the compound itself. [12] Conversion to a 
reactive epoxide species is a common step in the metabolism of 
potential carcinogens. [la] 
Polycyclic aromatic carcinogens have been most extensively 
studied, and are converted to electrophilic epoxide species in vivo. 
Vicinal diol-epoxides of the type shown in Figure 1. 2a are believed 
to be the ultimate carcinogenic form of these compounds. Bay 
region vicinal diol-epoxides are the most reactive form of epoxide 
possible in this class of compound. [7, la] 
Aflatoxins, which may cause some forms of liver cancer, are 
··---also converted to epoxides which subsequently react with cellular 
nucleophiles. [la] Aflatoxin Bl, a common contaminant of stored 
grain and nuts in Third World countries may be responsible for the 
high incidence of hepatic cancer and other liver disorders in 
these countries (Figure 1.2b). 
~lore recently, steroid hormones have been implicated in the 
aetiology of certain cancers. [la] Synthetic oestrogens such as ethin)'l 
oestradiol and diethylstilboestrol (DES) have been shown to form 
covalent links I<ith proteins and nucleic acids. [13] Epoxide 
derivatives of these tl<O compounds may be their ultimate carcinogenic 
species. (Fi~lre 1.2 c,d) [10,13] Proges~ins, androgens and bile salts 
7 OH 
(a) 
---
, 
o o 
(b) 
OH--C==CH 
, 
OH 
'Yl 
(c) 
--
HO HO 
OH OH 
(d) 
--
HO HO 
Figure 1.2. Carcinogenic compounds and their possible metabolic 
derivatives. 
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may also have carcinogenic activity after conversion to their 
reactive epoxide analogs. [13,14] 
A variety of viruses may cause c:tncer in humans. The acutely 
transforming retroviruses are capable of incorporating oncogenes 
from normal cells into their genomes. When the virus infects a 
cell it inserts its genome into the host cell as DNA. The viral 
promoter gene then initiates the synthesis of an oncogene product 
at the same time as its own components. .The resulting overproduction 
of the oncogene protein causes conversion of the normal cell to 
a neoplastic cell. [15] The chronic transforming retroviruses 
act simply by inserting their genome next to a cellular oncogene 
in the host cell's DNA. Viral promoter genes then initiate over-
expression of the oncogene. [15] Other viruses such as the 
hepatitis B virus, which causes liver cancer in humans, are known 
to insert themselves into the DNA of host cells but the mechanism 
of carcinogenesis is not understood. [16] 
Rearrangement of chromosomes, or translocations in normal cells 
can also cause cancer, notably Burkitt's lymphoma the cells of 
which have a characteristically abnormal set of chromosomes. [17] 
This process is believed to initiate carcinogenesis in normal cells 
if the translocation causes insertion of a cellular oncogene next 
to a cellular promoter gene. [18] 
A common characteristic of carcinogenesis is a latent period 
between initial contact with the carcino~en and development of a 
9 
neoplasm. [19] A two stage process is believed to occur in 
carcinogenesis. Ca) Initiation, which occurs on contact with 
the carcinogen, and Cb) Promotion which may occur years after 
the initiation phase and results from environmental factors, usually 
contact with 'cocarcinogenic' compounds. [19] 
Differences between normal and neoplastic cells 
Biochemical differences between normal and neoplastic cells 
are of interest for three reasons. 
Ca) They give clues to the causes of cancer 
(b) They aid the early detecti on of cancer 
(c) They may be exploitable therapeutically 
The main differences so far uncovered in neoplastic cells relative 
to normal cells are summarised in Table 1.1. 
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Table 1.1. Biochemical changes in cancer cells relative to 
normal cells. [3,11,20] 
Lower pH. 
Greater free radical character. 
Ectopic hormones. 
Altered enzyme profiles. 
Altered antigenicity. 
+ h· h + 1 Lower Ca and 19 er K leve s 
Elevated levels of methylated nucleosides. 
Higher levels of plasma mucoproteins 
and mucopolysaccharides. 
Altered mitochondrial structure. 
Elevated levels of polyamines. 
Greater need for exogenous Zn. 
Higher biowater content. 
Requirement for exogenous L-asparagine 
in some types (especially Leukaemias). 
Altered levels of cyclic nucleotides. 
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1.3 Cancer Chemotherapy 
Cancer chemotherapy involves the use of cytotoxic agents to 
kill neoplastic cell?, or of ho~mones to slow their proliferation . 
.. "i.~.{. 
The aim of chemotherapy is ·to eradicate neoplasms or' at least to 
reduce the patient's neoplastic cell burden and improve their 
quality of life. [21] 
Classes of anticancer drug, together with commonly used 
.examples are shown in Table 1. 2. The alkylating drugs, 0.£ major 
interest to the present work, are discussed in greater detail in 
the following section. The antimetabolites are active via 
inhibition of the metabolism of essential cellular intermediates, 
due to their structural similarity. Thus methotrexate, 
Methotrexate 
qn analog of folic acid competitively inhibits dihydrofolate 
reductase. [22] An important consequence of this is loss of 
thymidine. 
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Table 1.2. Classes of anticancer agents 
Drug class Examples 
Alkylating agents Cyclophosphamide, 
Myleran. 
(also see. page 18 ) 
Antimetaboli tes Methotrexate, 
5-Fluorourcil , 
6-Mercaptopurine. 
Antibiotics Dactinomycin, 
Mitomycin C, 
Adriamycin. 
Hormones Glucoc orticoids, 
Androgens, 
Oestrogens, 
Progestogens. 
Vinca Alkaloids Vincristine, 
Vinblast,ine. 
Miscellaneous Cis-platinum, 
L-asparaginase, 
Hydroxyurea, 
Nafoxidine . 
I 
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):N ~~,rN~ N H 
5-Fluorouracil 6-Mercaptopurine 
5-Fluorouraci 1 (5-FU) and 6-Mercaptopurine (6-MP) act as 
pyrimidine and purine analogs respectively. They are not them-
selves toxic, but become so on metabolism to their nucleotides. [22,23] 
- They are believed to act via inhibition of the enzymes involve in 
nucleotide metabolism and hence reduce the pool of nucleotide 
triphosphates available for nucleic acid synthesis. 6-MP and 
5-FU may be incorporated into DNA and RNA respectively, the contribution 
this makes to their cytotoxic activity is not clear. [22,23,24] 
The antibiotic anti-cancer drugs (Figure 1.3) all act either 
directly or indirectly on DNA functions. Adriamycin and 
Dactinomycin are intercalating agents and reduce both DNA and RNA 
syntheses in treated cells. [23,24] Other drugs in this class, such 
as mitomycin C and bleomycin do not intercalate DNA but cause either 
cross-linking of DNA, in the case of mitomycin C, or strand breaks 
as with bleomycin. (24) The antibiotic class of drugs has been used 
increasingly in recent years because of the broad spectrum of malignant 
14 
o CH 
o 
OH 
fcH~j 
H61 
NH2 
?i C-C~OH 
OH 
Adriamycin 
o 
11 
H2-0-C-NH2 
OCH3 
NH 
'--~ 
Mytomycin C 
Figure 1.3. Antibiotic anti-cancer drugs. 
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neoplasms they are active against. 
The steroid hormones, Figure 1.4, are used in a variety of 
disease states, on their own and in combination with other 
chemotherapeutic agents. Androgens and oestrogens are extensively 
used in treatment of breast and prostate cancers respectively. [25] 
Glucocorticoids are used in treatment of certain leukaemias as well 
as myelomas, lymphomas and breast cancer. Progestins are used 
predominantly in treatment of endometrial cancer, but may ~lso 
be used in breast and renal cancer. The steroid hormones are not 
curative. They produce remissions and may relieve symptoms. [25] 
They may also be used to reduce the side-effects of chemotherapeutic 
agents. [25] 
The Vinca alkaloids (Figure 1.5) act as 'spindle poisons'. 
These drugs bind to specific sites on tubulin in microtubules 
resulting in their dissolution. The compounds are specific for 
the mitotic phase of the cell cycle, and are used against a variety 
of cancers. [23] 
Several drugs used in arti-cancer treatment do not fit into 
any of the categories previously described and are grouped together 
in a miscellaneous class. Included in this group are enzymes, such 
as I-asparaginase which reduces levels of circulating asparagine. 
Neoplastic cells which are unable to synthesise this amino acid are 
effectively starved. [23] As would be expected this enzyme is 
only active against a rather narrow spectrum of malignancies and 
only affords remissions. 
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ANDROGENS 
OH 
o o 
Testesterone Methyltestosterone 
OESTROGENS 
HO"G==CH OH 
H HO 
Ethinyloestradiol Diethylstilboestrol (DES) 
GLUCOCORTICOIDS 
Prednisolone 
PROGESTINS 
o 
Medroxyprogesterone 
Figure 1.4. Natural and synthetic steroids used in 
cancer chemotherapy. 
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Vincristine RI = C02CH3 
R2 = CHO 
R3 = OCH3 
R4 = COCH3 
Vinblastine 
R = COCI-I3 
Figure 1.5. Vinca alkaloids used in cancer chemotherapy 
I 
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Hydroxyurea inhibits the enzyme ribonucleotide reductase 
o 
11 
H2N - C - NH - OH 
Hydroxyurea 
and kills cells that are synthesizing DNA. Thus cells in the S 
phase of the cell cycle are particularly susceptible. [26] Cis-platinums 
bind to DNA and inhibit its synthesis, they are believed to form 
intra-strand links with DNA. The cis-platinums are active in all 
stages of the cell cycle. [26] 
Cis-platin 
The 'choice of chemotherapeutic agent used depends on the type 
and state of the neoplasm. Use of combinations of chemothera peutic 
drugs, and improved scheduling of administration has markedly 
increased the effectiveness of chemotherapy. [27,2J] 
Alkylating agents as cytotoxic compounds 
Five major classes of alkylating agent are currently employed 
in cancer chemotherapy [29]; nitrogen mustards, ni trosoureas 
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triazenes, methane sulphonic acid esters and ethyleneimines. 
(Figure 1.6). All of these compounds are believed to react with 
nucleophilic hydroxy-, amino-, mercapto- or imidazole groups of 
proteins and nucleic acids. [11] The mechanism of action of the 
nitrogen mustards, the first of these drugs to be used clinically, 
has been more completely studied than any of the other classes. 
Nitrogen mustards are believed to exert their major cytotoxic 
effect by inter-strand linking of DNA, [29,30] and are therefore 
most cytotoxic to rapidly proliferating cells. [23] Of the other 
classes the ethyleneimines, such as Triethylenethiophosphoramide 
(Thio-TEPA) have a mechanism of action similar to the nitrogen 
mustards. Nitrosoureas such as carmustine (BCNU) alkylate nucleic 
acids and also carbamoylates lysine residues of proteins, this dual 
action gives the nitrosoureas a broad spectrum of action against 
tumours which are resistant to the other alkylating agents. [11] 
Methane sulphonate esters such as Busulfan ~re considerably less 
reactive than nitrogen mustards; the alkyl oxygen bonds split and 
the main mechanism of action is by alkylation of the N-7 position 
of guanine. [29] Triazenes such as dacarbazine also alkylate the 
N-7 of guanine. Dacarbazine is demethylated, producing 5-amino-imidazole-
4-carboxamide and a methyl radical. This radical is the active component 
which methylates the guanine of RNA and also attacks protein. 
Although all of the compounds described are presently in 
clinical use, and are potent anti-tumour agents, they suffer from 
the disadvantage of indiscriminate reaction with biological nucleophiles 
20 
Mustine 
Thio TEPA 
o 0 
11 11 
CH3-S-0-(CH2)4-0-S-CH3 
11 11 
o 0 Busulphan 
Dacarbazine 
Figure 1.6. Alkylating agents'used in cancer chemotherapy 
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and thus have limited therapeutic indices. Selectivity of action 
of these compounds depends mainly upon the relative rates of 
tumour and normal cell proliferation. Since several types of 
normal body tissue cells replicate at the same rate, or faster 
than tumour cells, toxic side effects are often pronounced. To 
overcome this problem, research with the alkylating drugs has 
centred on producing compounds with target-selective activity. [11] 
To this end considerable work has been carried out, both on 
improving the selectivity of drugs already in clinical use, and 
on developing alternative alkylating drugs which might be more 
selective in action. Among the types of compound 1<hich have been 
considered in recent years are a-methylene lactones and to a 
lesser extent epoxides. 
a-Methylene lactones 
The alkylating activity of the a-methylene lactone function 
has been kno1<n for many years. Simple synthetic a-methylene-
butyrolactone deri vati ves have been prepared for more than 
30 years. [32,33,34] H01<ever, the biological properties of this 
class of compound were only investigated follOl;ing their discovery 
as secondary metabolites in a variety of plants. [35] Cytotoxic 
sesquiterpene lactones, isolated during the course of a continuing 
search for anti-tumour agents from plants, were the first of the 
a-methylene lactone class of alkylating agents found to have anti-
tumour activity. [35] More than 500 of these compounds have been 
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isolated from the Compositae, [36] many of them exhibiting cytostatic 
and cytotoxic activity against animal tumours in vivo and against 
tumour cells in culture in vitro, some of the more well known 
of these compounds are depicted in Figure 1.7. [35,37,38] 
Structure-activity studies, both on the sesquiterpene lactones 
and on simpler model compounds have demonstrated that cytotoxicity 
in vitro is dependent on the presence of at least one 
a,S-unsaturated lactone group, with the a.S-ethylenic linkage 
being exocyclic. [37,38] Endocyclic a,S-unsaturated lactones are 
inactive. [39] The active compounds have been shown to undergo 
Michael type additions with biological nucleophiles. [39,40,41,42] 
Unlike the nitrogen mustards and other alkylating agents however, 
the a-methylene lactones apparently do not react with the purine 
bases of DNA. Testing of the compounds in vitro demonstrated a 
lack of reactivity with isolated DNA and also Ivith purine 
nucleotides. [30] HOIvever, the possibility of metabolic activation 
of the compounds prior to interaction Ivi th DNA has not been 
excluded. [30,43,44] On the other hand the active sesqui terpene 
lactones react rapidly and apparently irreversibly with thiol 
bearing molecules, such as cysteine, to form stable adducts. [39] 
(Figure 1. 8) Those compounds with endocyclic a, S-unsaturated lactone 
groups react only slowly [39J. 
101· 
I 
I 
OH 
lIelenalin 
Costulonide 
Eupatolide 
Figure 1.7. 
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101· 
o o 
Ha 
Tenulin 
o 
Parthcnin 
o 
Mexicanin 
Cytotoxic sesqui terpene a-methylene lactone 
compounds. 
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o 
X 
--0 
o 
H--- ---OH 
o -<S 
+H N 
3 CO-
2 
Figure 1.8. Cysteine adducts of cytotoxic sesquiterpene 
~-methy1ene 1actones. 
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Cytotoxic activity towards tumour cells in vitro is conferred 
simply by the presence of the reactive a-methylene group. However, 
additional functional groups are required for activity in vivo. ~7] 
Thus, with few exceptions, simple model compounds for example 
Figure 1.9, have low activities against experimental tumours 
in vivo. [45,46] 
~O 
Figure 1.9. Simple a-methylene lactone model compounds 
The more complex terpenoid compounds, such as 'elephantopin 
and vernolepin,have poor therapeutic indices, and are 
too toxic for clinical use. 
f"'" 
I ,OH 
Elephantopin Vernolepin 
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Attempts to produce compounds combining the low toxicity of the 
simple a-methylenebutyrolactones with the potent tumour-inhibiting 
properties of the terpenoids have so far proved unsuccessful. ~5,46,47] 
The mechanism of cytotoxicity of the a-methylene lactones 
is still unclear. Simple scavenging of cysteine and glutathione 
has been suggested, but is probably not of major significance. ~5,47] 
Alkylation of essential intracellular thiols, and possibly of 
membrane proteins is likely to be of greater importance. [48,49] 
Effects of sesquiterpene a-methylene lactones on the activities 
of a number of sulphydryl containing enzymes have been reported. 
Reaction with essential thiols of these enzymes has been 
determined as the mechanism of inhibition. Enzymes involved in 
glycolysis, [50,51] nucleotide metabolism and DNA synthesis, [30,52] 
have all been shown to be inhibited. 
Membrane functions, such as transport of amino-acids, sugars 
and nucleotides, [47,53] in addition to membrane-bound enzymes ~4,44] 
are perturbed by reaction with a-methylene lactones, and other 
thiol reagents. [54] 
The ability to inhibit cellular respiration is another property 
of the sesquiterpene lactones. [58] Both basal and ATP stimulated 
respiration is significantly inhibited in isolated cells and in 
liver homogenates [58,59] ,The mechanism of this activity is 
unclear, but may be caused either by alkylation of respiratory 
enzymes or of essential thiols on the mitochondrial membranes. 
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Lysosomal membranes are stabilised, and lysosomal enzymes 
inhibited by the sesquiterpene a-methylene lactones. This has 
prompted investigation of their properties as potential anti-
inflammatory drugs. [60] The dose levels required for anti-
inflammatory activity are considerably lower than those needed 
for anti-tumour activity in animals and hence toxic side effects 
are less evident. [60] 
Sesquiterpene a-methylene lactones are also cytotoxic against 
microorganisms, both to bacteria and simple eukaryates. [61] 
although concentrations higher than those required for anti-tumour 
activity are needed. 
The wide structural diversity of the sesquiterpene a-methylene 
lactones raised the hope that they might show some selectivity of 
action through their special stereochemical and molecular structures. [47] 
This initial optimism has not been realised. As with the classes 
of alkylating drugs already in clinical useage, these plant products 
have proved largely indiscriminate in activity. [46] However, the 
a-methylene lactone alkylating group has potent anti-tumour activity, 
and might still be of clinical use if linked to a molecule which 
conferred selectivity. 
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Epoxides 
The biological alkylating activity of the epoxides towards 
thiols and nucleophilic groups of DNA has been known for many 
years, mainly through research on their properties as carcinogens, 
as previously discussed. However, the alkylating activity of the 
epoxides has been employed in a number of anti cancer drugs (Figure 1.10) 
(62) 
~O~O~O~O~ Ethoglucid 
OH 
Mi tobroni to 1 
OH 
Figure 1.10. Epoxides used in cancer chemotherapy 
Unfortunately these compounds have proved to be of only limited use 
in chemotherapy and several drugs have been withdralffi from clinical 
use because of their toxicity. Attempts to produce epoxides with 
a more selective action have proved unsuccessful. 
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1.4 Breast Cancer 
Adenocarcinoma of the breast is one of the commonest forms of 
cancer in the developed world. It accounts for nearly 14% of all 
forms of cancer in the West. The disease has proved one of the most 
resistant forms of cancer to treatment. Five year survival rates 
in breast cancer patients have not significantly improved in the 
last 20 years. New forms of therapy are therefore constantly under 
review. 
Hormona! therapy and Chemotherapy 
Treatment of breast cancer following surgical removal of the 
primary tumour employs hormonal manipulations and/or chemotherapy, 
possibly in conjunction with radiotherapy. [25] The course of therapy 
depends on the oestrogen receptor state of the primary lesion. [63,64,65) 
Neoplasms with high oestrogen receptor levels (> 10 f moles mg- 1 protein) 
designated ER+ are normally responsive to hormonal manipulations 
initially. Neoplasms with low receptor levels « 3 f mol mg- 1 protein, 
ER-) tend to respond more favourably to chemotherapy. [64,65] 
Approximately 60% of primary and 50% of metastatic lesions have 
measurable levels of oestrogen receptor. [66,67] 
Prediction of which breast cancers are hormone responsive is 
obviously important for their subsequent treatment. The simple 
presence of oestrogen receptors does not positively identify hormone 
responsive lesions. [68) The predictive value of oestrogen receptor 
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assays on the primary lesion is improved by determining if the entire 
receptor mechanism is functional. [68] Several approaches are 
used to determine this, a) assay of oestrogen receptor-complexes 
associated with chromatin. [64,68] b) assay of levels of the various 
oestrogen receptor forms (45,55) [64] and c) assays of progesterone 
receptor levels. [69] 
Hormonal therapy produces minimal side-effects compared to 
chermotherapy. [25] It is not curative but long disease-free 
remissions can be produced. [65] The type of endocrine therapy 
employed depends on the age and condition of the patient. Treatment 
of premenopausal women is ablative; ovariectomy to remove endogenous 
oestrogens. [70] This has the added benefit of reducing oestrogen-
stimulated prolactin synthesis by the pituitary. [25] Prolactin 
stimulates growth in some types of breast cancer. 
In postmenopausal women oestrogens may be given at 
supraphysiological levers. [25] These high levels of oestrogen 
have a direct inhibitory effect on the neoplasm by antagonising the 
effects of prolactin. [25] Androgens may also be used, depending 
on the age of the patient. [70] Anti-oestrogens such as tamoxifen 
and nafoxidine (Figure 1.11) are being used increasingly in 
CH?, 
O(CH212-(J 
Nafoxidine , Tamoxi fen 
Figure 1.11. Anti-oestrogE;ns used in breast cancer therapy 
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postmenopausal women. [70] The mechanism of action of the anti-
oestrogens is unclear. They may block the binding of oestrogens, 
or the tamoxifen-receptor complex may have a direct lethal effect. [25] 
Both tamoxifen and nafoxidine are lethal to some human breast 
carcinoma cell lines,such as MCF-7. [25] In addition the presence of 
an anti-oestrogen receptor has been detected in cells from a number 
of sources. [71] The function of this receptor is unknown, but 
lines of MCF-7 cells resistant to anti-oestrogens lack the receptor. [71] 
Anti-cancer drugs of all the major classes are used in breast 
cancer chemotherapy. In ER- patients chemotherapy is the treatment 
of choice in all stages of the disease, as an adj uvant to surgery 
and in metastatic disease. However, in ER+ patients hormonal 
therapy is normally used as an adjuvant treatment and is replaced 
by chemotherapy when resistance to the endocine manipulations arises 
during the metastatic stage of the disease. Combined use of 
hormones and chemotherapy with ER+ patients is also used and is 
apparently better than either treatment alone. However, it 
is as yet unclear if this treatment improves on the sequential use 
of hormones and chemotherapy. [25] 
Combination chemotherapy, produces better results than any 
single drug. [65] However, no one combination regime' appears 
markedly better than others despite trials with a large variety of 
combination treatments. [65] The CMF regime (cyclophosphamide 
methotrexate, 5-fluorouracil) is one cif the most widely used treatments 
for disseminated breast cancer. [65] CMF treatment is employed in 
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combination with other drug protocols as well as on its own. [65] 
Progress in chemotherapy of breast cancer has been due less to 
improvement in drug design than to better use of existing agents. [72] 
Tailoring of chemotherapy to the individual patient, as well as 
better scheduling and dosage control increase the efficiency of 
treatment. [72] However, progress in these areas has served mainly 
to increase the length of remissions and improve the quality of 
life for the patient. Despite refinements in the application of 
endocrine and chemotherapy, management of breast cancer is achieved 
in less than 5% of patients 5 years after disease onset. [65] 
Steroid Receptors: Structure and Function 
The accepted mechanism of steroid hormone action on target 
cells has remained effectively unchanged for the past two decades. 
Steroid hormones are generally believed to bind to specific receptors 
in the cytoplasm which translocate to the nucleus by a temperature 
dependent 'activation' process, [73] , (Figure 1.12). This mechanism 
may have to be revised in the light of recent findings. It is 
possible that steroid receptors, for oestrogens at least, exist 
either exclusively in the nucleus or in an equilibrium between 
cytoplasm and nucleus. [74,75,76] These findings may explain the 
seemingly anomalous reports of the presence of 'unfilled' oestrogen 
receptors in the nuclei of both normal and neoplastic cells. [63,73,77] 
The temperature-dependent activation of oestrogen receptors is also 
apparently a nuclear event since both activated and non-activated 
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Figure 1.12. Models depicting the possible cellular distribution 
of steroid hormone receptors. 
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forms are found in the nucleus. [78] (Fig. 1.12) 
The mechanism by which the activated oestrogen-receptor complex 
(ER) alters gene expression in the chromatin of target cells is 
unclear. Binding of ER to chromatin leading to specific changes in 
m-RNA production has been demonstrated. [79] It is not known if 
the ER interacts directly with DNA, or via histone and non-histone 
proteins in the chromatin. (13,79,30] Some effects of steroid hormone 
action may be post-transcriptional; binding of ER to ribonucleoprotein 
in the nuclei and cytoplasm of target cells has been detected. [BO] 
The ER may be involved in stabilization of the messenger RNA of 
,hormone induced proteins and so faci li tate their production. [80] 
Oestrogen receptors exist as 45 monomers which commonly dimerise 
to 85 complexes at high salt concentrations. [13,81] On binding oestrogens 
the oestrogen - 45 complex is 'processed' to form. a 55 molecule 
which binds to chromatin. [73] The mechanisms involved in the 
interconversions of the molecular forms of receptor are currently 
under study. [82] Cyclic nucleotide levels, and protein kinases 
which phosphorylate the receptor proteins, are involved in receptor 
binding. [8~J 
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1.5 Steroid-Linked Cytotoxic Agents 
The use' of steroids as carriers of cytotoxic functions has 
been investigated for many years. It is an attractive route to 
increased selectivity since it exploits the known ability of target 
cells to concentrate steroids, via the hormone receptor mechanism. 
Cytotoxic-linked steroids should therefore be expected to concentrate 
in receptor positive neoplasms. 
Initial work on steroid-linked alkylating drugs was undertaken 
primarily with a view to exploit the lipophilicity of the steroid 
nucleus, to improve drug transport, as well as directing the drug to 
specific target tissues. [84] The first steroid-linked alkylating 
compounds tested '<ere relatively inactive, [84] with the exception of 
the cholesterol deri vati ve phenestrin, (Figure 1.13) which was active 
against a number of experimental tumours in animals. [84] The success 
of phenestrin prompted the synthesis and evaluation of several nitrogen 
mustard and ethylene imine steroidal compounds, (Figure 1.13) some of 
which reached the clinical trial stage. [84,85,86]. CL-~lethylene lactones 
linked to steroids were synthesi sed, follOl<ing the ,<ork on the nitrogen 
mustard and ethylene imine compounds, and found to be active against 
neoplastic cells in culture, in addition to animal systems. [86,87,88] 
(Figure 1.13). 
Steroid-linked alkylating drugs up to this point had been 
produced without regard to their ability to bind to specific hormone 
receptors in the neoplasms they were designed to treat, such as 
malignancies of the breast and prostate. Improved design of these 
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Figure 1.13. Early nitrogen mustard and ethyleneimine and Cl-methylene 
lactone steroidal compounds. 
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drugs was possible with development of structure-activity profiles 
of steroid receptor binding sites using competitive binding assays. [89, 
90] Research on the molecular biology of steroid hormone action 
has also contributed to development of this class of drug. [91,92] 
A systematic screening programme has been developed by several 
groups to assess oestrogen-linked alkylating drugs as possible agents 
in treatment of breast cancer. [93,94,95] The programme involves three 
steps. 
(a) In vitro screening of compounds for receptor binding. 
(b) Cytotoxicity assays on two human breast cancer cell lines; 
~ICF-7 \;hich has oestrogen receptors (ER+), and Evsa-T which 
does not (ER-). 
(c) In vivo effects, on dimethylbenzanthracene (DMBA) induced 
mammary neoplasms in rats and the hormone dependent MXT-mouse 
mammary neoplasm. 
However, not all \;orkers agree with this mainly in vitro screening 
procedure. [96] 
Several of a series of nitrogen mustard-linked oestrogens displayed 
acti vi ty in the first two phases of this programme. [93,97] (Figure 1. 14a) . 
The drugs exhibited some degree of selectivity towards the ER+ cell 
line. The receptor binding of these compounds was poor compared to the 
parent oestrogens ho\;ever, and further work is undeI1;ay to improve their 
affinity for the oestrogen receptor and hence their selectivity. [98] 
More recently a series of thiourea-linked oestrogens were found to 
exhibit no selectivity against ER+ cells, this was attributed to their 
lack of receptor binding activity. [9~] (Figure 1.14b). 
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Figure 1.14. Nitrogen mustard,and thiourea derivatives of 
oestrogens. 
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Cytotoxic stilbene oxide anti-oestrogen compounds have also been 
tested for oestrogen receptor binding and for in vivo antitumour 
activities. [100] (Figure 1.15) The 3,3'-dihydroxy-cx,S-ciialkyl-
stilbenes arc anti-oestrogenic, and have strong mammary tumour 
RI RI 
& R2 
CH3 OCOCH3 
C2HS OCOCll3 
C2Hs OH 
Figure 1.15. 3, 3' -Dihydroxy-a, l3-dialkylstilbenes and 
related stilbene oxides 
inhibiting properties III :mimal systems. Unfortunately the corresponding 
oxides did not show increased activity, although their receptor 
binding was equivalent to the parent stilbenes. The lack of increased 
antitumour activity is attributed to the poor reactivity of the 
epoxides. [100] 
A diverse series of hexestrol derivatives (Figure 1.16) initially 
synthesized as affinity labelling reagents for the oestrogen receptor, 
O'R 
R ~ = LBr 
R = 
HO Cl R = 
R Br = 
Figure 1.16. A1ky1ating derivatives of hexestrol 
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are also currently undergoing tests to determine if they are selectively 
cytotoxic to ER+ cell lines. [101] A number of these compounds have 
been shown to alkylate and inactivate the oestrogen receptor. 
Oestrogens with ~inked alkylating groups may have a dual action 
on receptor positive tumours. They may alkylate and inactivate the 
receptor, effectively acting as an anti-oestrogen,or they may bind non-
covalently to the receptor and be released in the target cell nucleus, 
to alkylate cellular nucleophiles. There is evidence that both 
mechanisms may be involved in the action of these drugs. Irreversible 
binding, indicating possible covalent attachment, to the oestrogen 
receptor has been noted in several test compounds. [93] Thiol groups 
on the oestrogen receptor play an important role in ligand binding, 
and may be located in the binding site itself. [102,103] Alkylating 
oestrogens could react with receptor thiols during the binding process. 
In this way the alkylating compounds act as anti-oestrogens by 
blockade of the receptor. This process is sufficient to inhibit 
growth in some hormone responsive tumours in vivo, and cell lines 
in vitro. [104, lOS] 
Dissociation of cytotoxic oestrogens from receptors and subsequent 
reaction with cell components is preferable in tumours which although 
containing ER are not oestrogen dependent. To this end the cytotoxic 
oestrogen should not bind covalently to oestrogen receptors. [106] 
The development of steroid-linked cytotoxic drugs as selective 
anti-cancer agents, has only become quantitative relatively recently. 
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The initial results seem encouraging, but there is room for considerable 
improvement in the selectivity of this class of drug. This should 
prove possible using newer methods for screening potential drugs of 
this class. Also the continued research on the mechanisms of steroid 
hormone receptor action in cells should prove helpful in new drug 
design. 
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1.6 Scope of Work 
The aim of this project was to produce compounds selectively 
toxic towards oestrogen receptor containing neoplasms, as agents 
for the treatment of breast cancer. It was proposed to do this 
following the scheme described below. 
(1) To design an in vitro assay system to evaluate the cytotoxicity 
and potential selectivity of alkylating derivatives of 
oestrogens. 
(2) To use this system to examine a series of D-ring a-methylene-
a-lactone derivatives of oestrogens produced by the Organic 
Chemistry Section at Loughborough. 
(3) To use the structure-activity data so gained in the design 
of compounds with improved selectivity. 
(4) To evaluate the mode of action of these and related compounds 
in an attempt to identify potential biochemical targets. 
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2. MATERIALS AND METHODS 
44 
2.1 Materials 
2.1.1 Cell Culture 
Cell Lines: HeLa S3 and GH3 cells were supplied by Flow Laboratories 
(Irvine, Scotland). MCF-7 cells were kindly provided by the 
Cell and Tissue Culture Laboratory ICI Pharmaceuticals Division, 
Alderley Park. 
Media and Plastics: Culture media, serum and balanced salt solutions 
"ere obtained from Flo" Laboratories. Plastics (75 cm2 flasks 
and 25 cm2 dishes) were obtained from Corning (Stone, England). 
Instrumentation: Cells were maintained in a Grant incubator, 
Aseptic procedures were performed in an HO\;arth Laminar Flow 
cabinet. A Coulter Counter ~Iodel ZB "as used for cell counting, with 
Isoton 11 balanced electrolyte solution, Coulter Electronics, Luton, Englar 
2.1.2 Steroid Binding Assays 
Animals: Female Wistar rats «50 g) obtained from the Animal Unit, 
Sutton Bonington, University of Nottingham, "ere used for all 
uterine receptor binding studies. 
T. E. D. Buffer: (Tris (hydroxymethyl) aminomethane) 10 w! 
Ethylenediaminetetraacetate (E.D.T.A.) 1.5 mM 
Dithiothreitol 0.5 mM 
Adjusted to pH 7.4 with dilute HCl 
Radiochemicals: [6,7-,3HJ Oestradiol (49 Ci mmol- 1) was supplied 
by Amersham International (Amersham, England). 
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Chemicals and Biochemicals: All Chemicals and Biochemicals used 
in binding assays were purchased from Sigma or Aldri ch, 
(Gillingham, England). PCS scintillation fluid was supplied by 
Amersham International. 
Instrumentation: Cytosols were prepared using an ~ISE Superspeed 
MK 11 centrifuge. Radioactivity was measured using a Phillips 
PW 4700 liquid scintillation counter. 
Pyruvate kinase activity: Pyruvate kinase/lactate dehydrogenase 
enzyme preparation was supplied by Sigma. 
Imidazole Buffer: Imidazole 
KCl 
50 mM 
120 mM 
MgS04 30 mM 
pH adjusted to 7.6 using dilute HCl 
Chemicals and Biochemicals for the enzyme assay were obtained from 
Sigma. 
2.1.3 Biochemical Studies 
Animals: Female Sprague - Dawley rats supplied b,· the Animal Unit, 
Nottingham University \;ere used as a source of Ih·er tissue for 
oxidative phosphorylation and lysosomal membrane studies. 
I>Ii croorganisms: Escherichia co 1 i NClB 9001, Candida albicans A39 
(clinical isolate obtained from Boots, Nottingha::l) and Penicillium 
chrysogenwn Oil :6:11 \;ere used in assays to assess toxicity on 
prokaryotes and simple eukaryotcs. 
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Media: 
Fungal and Yeast Media. 
Maltose 
Yeast Extract 
Mycological Peptone 
Malt Extract 
pH adjusted to 5.0 
Nutrient Broth: Beef Extract 
Neutralized 
NaCI 
pH adjusted 
38.0 gl-l 
2.5 gel 
8.0 gl-l 
20.0 gl-l 
Bacteriological 
to 7.5 
10.0 gl-l 
Peptone 10.0 gl-l 
5.0 gl-l 
All media ingredients for culture of micro-organisms were obtained 
from Oxoid Ltd., (Basingstoke, England). 
Buffers 
Oxidative Phosphorylation 
S.T .E. Buffer: 
Assay Buffer: 
Na+/K+ ATPase assay: 
Sucrose 250 mM 
Tris lmM 
E.O.T.A. 1 mM 
KCl 75.0 mM 
Tris 50 mM 
KH2P04 12.5 mM 
MgC12 5mM 
E.O.T.A. 1 mM 
a-ketoglutarate 10 mM 
pH adjusted.to 7.4 
Tris 92 mM 
NaCl 60 mM 
E.O.T.A. 0.1 mM 
KC! 5 mM 
MgS04 5 mM 
pH adjusted to 7.5 
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2.1.4 Electron Microscopy 
Fixative solution: Gluteraldehyde 
Formaldehyde 
HtJ 
0.32M KCl/0.04M Mg Acetate 
25 ml 
15 ml 
10 ml 
50 ml 
Fixative stock solution was mixed with an equal volume of Earle's 
balanced salt solution before use. 
Washing solution: Sodium cacodylate 0.05 M 
KCl 0.08 M 
Mg Acetate 0.01 ~1 
Veronal Acetate Buffer: Na Acetate 0.24 M 
Na Barbitone 0.14 M 
NaCl 0.6 M 
5 ml of the basic solution was mixed with 7.0 ml 0.H1 HCl, 13.0 ml 
H20 and 0.25 ml HI CaC12 to give a pH of 6.1. 
48 
2.2 Methods 
2.2.1 Maintenance of Cell Lines 
HeLa S3 cells 
HeLa S3 (cervical carcinoma) cells were grown in Eagle's Minimum 
Essential Media supplemented with 10% foetal bovine serum, 2mM 
L-glutamine, 1% non-essential amino acids and the antibiotics penicillin 
(50 IU ml- l ) and streptomycin (50 ~g ml- l ). 
Cells were incubated at 37°C with a 5% C02/air humidified 
atmosphere. Under these conditions the generation time was approximately 
24 hours (Results,Figure 3.1). Stock cells were grown in 75 cm2 
flasks and subcultured at 3-5 day intervals. Cells were removed 
from monolayers using a 0.25% trypsin solution, and harvested with 
Earle's Balanced Salt solution. For biochemical assays cells were 
removed by scraping with a 'policeman' to detatch monolayers. 
GH3 Cells 
GH3 cells (rat pituitary adenoma) cells were grown in Ham's F-lO 
Media supplemented with 2.5% foetal bovine serum, 15% donor horse 
serum, 2mM . L-glutamine, penicillin (50 IU ml- l ) and streptomycin 
(50 ~g ml Cl ). The cells were incubated as for HeLa S3 cells. 
Generation time was approximately 33 hours, (Results, Figure 3.1). 
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Storage of Cells 
Cell lines were prepared for storage in liquid nitrogen by a 
modification of the method described by Paul. [107] Cells were 
harvested and resuspended in media containing 15% serum and 10% 
dimethyl sulphoxide to a density of 5 x 106 cells/ml. 6 ml Aliquots 
in storage tubes were cooled in an ice/water bath for 30 minutes, 
then transferred to a freezer at -20°C for 4 hours and finally to 
storage in liquid nitrogen vapour. 
Ce 11 Counting 
Cells were counted using a Coulter Counter model ZB with a 
140uM diameter orifice tube. Cells were first sized, Figure 2.1, 
and appropriate instrument settings used thereafter to count HeLa 53 
or GH3 cells. 
2.2.2 Cytotoxicity assays using cell cultures 
HeLa 53 cells 
Compounds were assayed following the Cancer Chemotherapy National 
Service Centre (CCNSC) protocol for KB cells [108] Cell numbers were 
determined as described by Coulter Counter. Growth inhibition curves 
were plotted from mean cell counts after 48 hours. 2.5 x 105 Cells 
in 5 ml media were seeded in 25 cm2 dishes. After incubation for 
24 hours the media was changed. Control dishes were counted to give 
baseline cell numbers and test compounds added in 25 ul DMSO 
(0.5% final concentration). 
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Figure 2.1. Size distribution of GH3CO) and HeLa S3 Co) cells. 
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Compounds were screened initially at concentrations between 
10 and 0.5 vg ml- 1. Those which significantly inhibited growth 
below 10 llg ml- 1 were re-assayed to produce dose vs inhibition of 
growth curves. Compounds with little or no acti vi ty at 10 llg ml- 1 
were re-assayed at 20 llg ml~1 in triplicate. 
GH3 cells 
Activity of compounds against GH3 cells was determined by a 
modification of the procedure described for the HeLa S3 line. To 
take account of the longer generation time of the GH3 cells, a drug 
contact time of 66 hours was used, after the initial 24 hour 
incubation. 
MCF-7 cells 
Assays using MCF-7 cells (performed at I.C.I.) were carried out 
in 1 ml multiwell tissue culture dishes. 1.5 x 105 Cells were 
seeded in 1 ml of medium (containing dextran/charcoal stripped serum) 
and incubated for 24 hours. Following incubation the media was 
replaced I<ith 1 ml of fresh media containing test compounds added 
10 III DMSO (0.5%). Control I,ells I<ere counted in triplicate to 
determine baseline numbers. A model ZM Coulter Counter I<as used 
open channels; counts were corrected for background. 
A drug contact time of 72 hours after the initial 24 hour 
incubation was used. 
in 
with 
• 
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2.2.3 Steroid Binding Methodology 
Receptor assays 
Uterii from oestradiol benzoate-treated immature (2 day old) 
rats (0:16 ~g/s .c. in arachis oil daily x 3) were homogenised in 
TED buffer at 4°C. The homogenate was centrifuged at 100,000 g for 
1 hour (4°C) and the cytosol used immediately. Cytosol (150 Ill) was 
incubated with varying concentrations of competing ligands added in 
TED buffer (SO ~l) and [3Hl oestradiol (35nM, SO Ill) in TED 
buffer at 30°C for 30 minutes. Parallel incubation of cytosol 
(150 ~l) and 50 ~l of a solution of diethylstiboestrol (5 IlM) 
in TED was used to determine the specific binding of [3H] oestradiol. 
All tubes were then cooled in ice/I<ater for 15 minutes after 
loJhich 200 ~l of a suspension of dextran coated charcoal (250 mg% 
Norit-A, 2.5 mg% dextran) in TED buffer was added and the tubes 
allowed to stand for 20 minutes in ice/water with occasional 
vortex mixing. Tubes were centrifuged (2000 g x 5 minutes) and 
200 ~l aliquots of supernatent were added to 5 ml PCS and counted . 
Counting efficiency was 30-35 9,. 
Cytosol containing oestrogen binding sites I,as obtained from GH3 
cells by a modification of the method according to Roos et al. [109] 
Attached cells were washed 3x with TED buffer 4°C, scraped from the 
plates and suspended at a final concentration of 107 cells ml- I . The 
suspension was sonicated, (2 x 5 second bursts) at 4°C, and the resulting 
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suspension was centrifuged at 100,000g for 1 hour. The supernatants 
were used immediately in binding assays, as described for rat uterine 
cytosols. 
Role of thiols 
To determine if reaction with thiol groups in cytosols reduces 
avai labili ty of drugs for binding during competitive binding assays, 
bromoacetone treated cytosols were used as described by Katzenellenbogen. 
[lOll 
The effect of bromoacetone on specific binding in cytosols was 
first determined. Uterii from three oestradiol-benzoate treated 
rats were excised and the horns divided. The horns were then randomly 
spli t; three were homogenised in TED buffer, three in buffer without 
dithiothreitol (TE buffer). The homogenates were centrifuged 
(lOO,OOOg x 1 hour) and the cytosols used immediately. 
Cytosol in TE buffer was assayed for SUlphydryl groups; 200 \11 
cytosol added to DTNB solution (1 \1 mole in 2.8 ml phosphate buffer) 
and the absorbance measured at 412 nm. The cytosol was then divided 
in two. Half was treated with a four-fold excess of bromoacetone, 
which reduced thiols to below measure able levels and then specific 
binding in both treated and untreated aliquots was determined as 
described previously. Cytosol in TED buffer was assayed for specific 
binding as normal. 
Receptor binding of drugs in bromoacetone-treated cytosols was 
determined by preparing cytosol in TE buffer and treating with four 
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fold excess of bromoacetone. Drugs were used in the binding assay 
at 2.5 ]JM. Dose/response curves for diethylstilboestrol "ere also 
measured to ensure that the characteristics of the oestrogen receptor 
were not altered by the treatment. 
Reversibility of drug/receptor binding 
Reversibility of drug/receptor binding was determined according 
to the method described by Katzenellenbogen. [101] This wethod makes 
allowance for any loss of receptor binding that may occur due to 
denaturation of the receptor protein. 
Cytosol was prepared as described from immature rat uterii. 
150 ].ll Aliquots were incubated with saturating concentrations of 
ligands, control tubes contained 30 n~1 oestradiol, in a final volume 
of 250 ].ll. TIle tubes were incubated for 16 hours at 30°C. A 
parallel incubation \vas first 'protected' with 30 n~1 oestradiol 
(1 hour, 4°C), to fill the receptor binding sites, before addition 
of the alkylating compounds. 
After 16 hours incubation all the tubes were cooled to 4°C 
and treated with dextran/charcoal suspension (200 ].ll) as described 
previous ly, to remove unbound ligands. 
Two 150 ].ll aliquots of supernatant were taken from each tube. 
One aliquot was incubated \d th 7 n~1 [3H]-oestradiol and be other 
wi th 7 n~1 [3H]-oestradiol plus 1 ].l~1 'cold' oestradiol in a final 
volume of :50 ].ll. The tubes \vere incubated for a further 16 hours 
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at 30°C. After this final incubation the tubes \;ere cooled to 4°C, 
and treated with dextran/charcoal suspension. 200 ~l Aliquots of the 
supernatants were added to 5 ml PCS and counted. 
Effects of drugs on allosteric enzyme activity (Pyruvate kinase) 
Pyruvate kinase (PK) activity was measured in a coupled assay 
system, with lactate dehydrogenase (LDH) at 25°C in 50 mM imidazole 
buffer pH 7.6 by spectrophotometric determination of NADH disappearance 
at 340 nm. [110] 
Assay mixtures consisted of 2 mM adenosine diphosphate (ADP), 
3 mM phosphoenolpyruvate (PEP) and 1 m~I nicotinamide adenine 
dinucleotide reduced form (NADH) in a total volume of 3.0 ml. 
Reactions Kere started by addition of 0.1 ml PK/LDH solution, 
(10 ~g enzyme/ml- 1 in buffer). The reaction \;as followed using 
a SP 500 spectrophotometer linked to a Vitatron chart recorder, 
constant temperature was maintained in the spectrophotometer by a 
water jacketed cu\·ette rack. Compounds were added in D~ISO up to 
a final concentration which did not exceed 10%. D)ISO up to a 
concentration of 10~ did not adversely affect activity. 
2.2.4 Biochemical Studies 
Electrophilic acti vi t)' of compounds 
Each compound under test (1 ~mole) in 0.9 ml D:,ISO 
was added to 2.1 ml phosphate buffer pH 7.8 at 25°C containing 1 ~mole 
of glutathione. 200 ~l Samples were taken at intervals and unreacted 
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glutathione determined by Ellman' s method [Ill] as follows; samples 
were added to 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB) solution 
Cl ]Jmole in 2.8 ml phosphate buffer pH 7.0) and the change in 
absorbance measured at 412 nm. 
Effect of drugs on cellular thiol levels 
2 X 106 Cells in 5 ml media were placed in 25 cm2 dishes and 
incubated overnight. Drugs were added in 25 ]Jl DMSO (0.5%), and the 
cell incubated for various times. Attached cells "ere "ashed twice 
"ith Isoton (4°C), harvested and suspended in 5 ml Isoton. The 
suspension was cenaifuged (600 g x 5 minutes), and re suspended in 
500 III Isoton. 
Cell surface tOliols were determined by reacting 100 III of cell 
suspension with 1.4 ml DTNB solution (1 mM in phosphate buffer pH 7.0) 
for 5 minutes at room temperature. TIle reaction \;as stopped by 
centrifugation (600 g x 5 minutes) and absorbance of the supernatant 
measured at 412 nm. 
Total cell thiols were determined by sonicating the remaining 
cell suspension. The sonicate (100 ]Jl) \;as added to 4.1 ml DTClB as 
above. After cent::-ifugation (11,000 g x 5 minutes) the absorbance 
was measured at 41: nm. 
Viability of cells after treatment with drugs "as measured after 
staining with nigrosin. 
57 
Lysosomal membrane stability and lysosomal enzyme activity 
Labilisation or stabili sation of lysosomal membranes \,as assesed 
by determining the release of the marker enzyme aryl sulphatase. [112] 
Livers from female Sprague/DaHley non-fasted rats (approx. 250 g) 
were removed, Heighed, and homogenised in 0.25 M sucrose -0.02 M Tris 
pH 7.4, (4°) to give a 10% homogenate using a TR l-R K41 glass-teflon 
homogeniser. The homogenate was centrifuged (600 g x 10 minutes, 4°C), 
and the supernatants diluted with an equal volume of the same buffer 
and centrifuged (1500 g x 15 min, 4°). The supernatants \,ere used 
immediately as the source of lysosomes. 
A suspension of the lysosome-containing liver fraction \;as 
warmed to 25°C for 5 minutes, then 0.2 ml samples \;ere added to 2 ml 
buffer with or without drug (added in DMSO, 0.59, final concentration) 
and incubated at 37° for 1 hour. 0.5 ml Samples of the incubation mixture 
Here then used in the enzyme assay as follows:-
Aryl sUlphatase activity Has determined by adding 0.5 ml of 
incubation supernatant to 1 ml of 0.2 M acetate buffer pH 5.8. 
Incubations (37°C, 20 mins) were initiated by addition of 50 lJl 
substrate (p-ni trocatechol sulphate, 25 mg/ml in distilled H20), and 
terminated by addition of 100 lJl of 4N sodium hydroxide. Absorbances Here 
measured at 510 nm, ::md compared \,ith total activity obtained as 
follows: -
An aliquot of the lysosomal liver fraction \,as incubated with 
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0.2% triton x-lOO for 1 hour at 37° to totally disrupt lysosomal 
membranes. The resulting preparation was then assayed for aryl 
sulphatase activity, as described above, but in the presence of drugs, 
(added in OI-ISO, 0.5%). 
Oxidative Phosphorylation 
Respiration in 10% liver homogenates of rats was measured using 
a Cl ark Oxygen Electrode, with a 2 ml reaction vessel volume, connected 
to a Vitatron recorder:-
Li vers from female Sprague/Da\dey rats were excised, \;eighed and 
homogenised in STE buffer pH 7.4 at 4°C to give a 10% homogenate 
(w/v). TIle homogenate was centrifuged (600 g x 10 mins, 4°) and 
the pellets discarded. The supernatants were centrifuged 
(8,500 g x 10 min, 4°) the pellets resuspended in buffer and centrifuged 
again under the same conditions. TIle resulting mitochondrial pellet 
Has resuspended in STE buffer, approximately 1 ml per gram of original 
tissue to give a suspension of 20-30 mg of protein per ml (Lowry 
estimation). [113] 
The 02 electrode was calibrated by addition of saturated 
di thion ite solution (lOO Ill) to fresh assay media in the \Oessel, to 
give a full scale deflection. Reactions were initiated by addition 
of 100 III of mitochondrial preparations to 2 ml of assay media and 
the rate of state 4 respiration measured for several minutes, 100 III 
of a 5.6 I!U\I oHP sol ution in assay media Has then added to obtain the 
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state 3 rate of respiration. Effects of compounds on the rates of 
respiration I;cre measured both by addition of the drugs to the reaction 
vessel (in 10 ).11 DMSO, O.S?'), and by preincubation of the mitochondrial 
preparation with drug before use. 
[3Hl Thymidine uptake and incorporation in HeLa S3 cells. 
Uptake and incorporation of [3H] thymidine was determined according 
to the techniques described by Woynarowski and Konopa [43] 
(a) Uptake of [3H} thymidine: 
HeLa S3 cells in log phase of growth I,ere harvested, resuspended 
in Minimum Essential "Iedia, (MEM) for suspension cultures (pH adjusted 
6 - 1 to 7.4), to give a stock ccll suspension of 1.05 x 10 cells ml . 
Stock solutions of [3H] thymidine in ~IEH I;ere made up with labelled 
and' cold' thymidine to give a solution of 0.45 n moles th)1TIidine 
-1 (0.75 IJ Ci) ml . 
Incubations were initiated by addition of stock cell suspension,to 
thymidine,solutions in the ratio 1:2. to give an inoculate containing 
3.5 x 105 cells, 0.3IJmoles, O.SIJ Ci ml- 1 . Incubations I,ere at 37°C 
in a shaking \Vater bath, 70-80 oscillations per minute, for varying 
times and I,ith varying concentrations of test drug, (added in o;ISO, 0.5°,). 
After incubation 0.5 ml aliquots of ce 11 suspens ion I,ere collected 
by filtration using a vacuum manifold on IVhatman GF/C glass fibre filters. 
The fil ters I,ere I;ashed I;i th isoton 4 ° (3 x S ml), placed in 
scintillation vial inserts and counted in 5 ,ml, PCS. 
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(b) Incorporation of [3H] Thymidine: 
Cells were harvested and suspended in ice cold MEM for suspension 
cultures to a density of 3.5 x 105 cells/ml. [3H] Thymidine was 
added to give a concentration of 2 u Ci ml- 1 and the cells incubated 
for 1 hour at 6°C. The suspension was then centrifuged (600 g x 5 mins, 
4°C), and the cells washed twice with ice cold media and resuspended 
in fresh media. Drugs were added (DMSO) and the cells were incubated, 
under the same conditions as described above, for 30 minutes. Incubation 
was terminated by removal of 0.5 ml aliquots of suspension and the 
cells collected by centrifugation (600 g x 5 mins). The supernatant 
was then aspirated and the cells resuspended in 200 ul ice cold 109, (IV/V) 
TCA and left overnight (4°C). Precipitated macromolecules I,ere 
centrifuged (11,500 g x 5 min) and resuspended in 250 ~l 5% TCA 
and hydrolysed by heating (70°C, 1 hour). 200 \.11 samples I,ere then 
counted in 5 mt PCS. 
+ + Adenosine triphosphatase (NA /K ATPase) activity 
a) Isolated enzyme assays 
ATPase from HeLa S3 cells in addition to commercial en:yme 
preparations I,as used to determine the effects of drugs. .-\TPase 
from HeLa cells was prepared from cells harvested in earl)" log phase. 
The cells I,ere resuspended in distilled water and sonicated (3 x 5 sec 
bursts), and the protein concentration adjusted to approxi::1ately 0.5 mg 
ml- 1 . (LOI{r~· estimation). 111is suspension was then used in the 
enzyme assay. Commercial en:ymes I;ere adj usted to give an enzyme 
activity of 0.05 units ml- 1 . 
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ATPase activity was determined by measurement of the release 
of inorganic phosphate according to the method of l-lartin and Doty. [114] 
Enzyme suspension (0.1 ml) was added to 0.8 ml of Tris buffer 
pH 7.5 with or \;i thout drug (added in DMSO). Reaction was started, 
after 10 minutes equilibration at 37°C, by addition of 0.1 ml ATP 
solution (40 nu"! in distilled lVater) and terminated by the addition of 
1 ml of cold 10% TCA. 
Reaction mixture (1 ml) lVas taken and added to tubes containing 
2.5 ~l of HzO saturated isobutanol/benzene (1:1 mixture) and 1 ml of 
ammonium molybdate solution Cl.25% in 0.5 M HzS04). The tubes lVere 
vortex mixed for 15 seconds each then centrifuged, 2000 g x 3 mins, 
to separate the layers. 1 ml Of the isobutanol/ber.zene layer was 
taken and added to tubes containing 2 ml of ethanol-H2S04 (980 ml 
ethanol: 20 ml conc HzS04) and mixed, 0.1 ml of a solution of 
stannous chloride (40 g SnClZ in 100 ml conc HCL diluted 200 x wi th 
0.5 ,I HZS04) were added and the colour allowed to develop. The 
absorbances of the solutions were measured at 730 nm. 
(b) 86Rb+ uptake by HeLa S3 cells 
2.5 X 105 Cells in 5 ml media were seeded in :5 cm tissue culture 
dishes and incubated for 24 hours. After 24 hours the media \,as 
replaced with fresh media containing 0.5 u Ci 8 6Rb + ml -1. Drugs 
were added in 25 ul D~ISO (0.5',). After incubation for various times 
the media was aspirated and the cells washed with Tris buffer pH 7.4 
(3 x 1 ml). 86 Rb + "as extracted in 0.5 ml 59, TCA solution. A 250 ul sample 
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of extract was then added to 5 ml PCS scintillation fluid and radio-
activity counted. 
Toxicity of drugs against microorganisms 
The effects of the compounds on growth of bacteria, fungi and 
yeasts was determined. 
(a) Escherichia coli (E. coli) 
E. coli starter cultures were grown in nutrient broth over-
night in a shaking water bath at 37°C. 1 ml Aliquots ofstarter 
culture were then innoculated into tubes containing 5 ml nutrient 
broth and allOl,ed to reach log phase by incubating for 2 hours at °C. At 
this (zero) time the turbidity in control cultures was measured at 
650 nm. Test compounds I,ere added in 50 III DMSO and the cultures 
incuba ted for a further 3 hours when the turbidity was again 
measured. Inhibition of grOl'th was defined as a slowing of the 
turbidity increase compared with control tubes. 
(b) Candida albicans, and Penicillium chrysogenum. 
Slope cultures of the organisms I'ere transferred to 50 ml of 
fungal media and incubated at 30°C for 48 hours. 0.5 ml A1iquots 
were then transferred to tubes containing 4.5 ml nutrient :::edia. 
Steroids and Cl-methylene lactones were added in 125 ).11 O:-ISO (~.5'j), 
and the cuI tures incubated at 30°C for a further 48 hours "hen the 
turbidi ties I'ere measured at 650 nm. Inhibition of grOl;th "as 
determined from reductions in turbidity over 48 hours in the case of 
C. albicans and by dry weight. 
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2.2.5 Electron Microscopy 
(a) Scanning Electron Microscopy 
1.0 x 106 Cells in 5 ml media \Vere added to 25 cm2 tissue culture 
dishes, containing 33 mm diameter covers lips , and incubated for 24 hours 
to allow the cells to adhere to the covers lips . After 24 hours the 
media was replaced and compounds added in 25 III D~150. The cells Ivere 
incubated for a further 24 hours. 
Treated and untreated cells were then \Vashed I,i th Earle r s balanced 
salt solution (2x) and Ivi th \Vashing solution (2x). The cells \Vere then 
covered \Vith fixative solution at 4°C and left overnight. After 
fixation the cells Ivere rinsed Id th balanced salt solution (2x) and 
then with distilled \Vater (3x). The fixed cells I'ere dehydrated in 
a vacuum dessicator overnight. 
The covers lips \Vi th attached cells \Vere removed and gold coated 
(10 nm). TIle cells were then examined in an Alpha 9 scanning electron 
microscope [115], at a magnification of lSOOx. 
(b) Transmission Electron mcroscop)' 
2 x 106 Cells in 10 ml media were added to 75 cm2 tissue culture 
flasks and incubated for 24 hours, Ivhen the media h·as repl:J.ced and 
compounds added in 50 )11 0"150. TIle cells Ivere incubated for a further 
24 hours. 
Treated and untreated cells Ivere \Vashed \Vi th Earle' s balanced 
salt solution (2x) and Ivashing solution (2x). Fixative solution (4°C) 
Ivas then addt'd and the cells Ivere fixed overnight at 4°C. After fixing 
the cells \Vere rinsed with \Vashing solution (2x), collected by 
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scraping and centrifugation (600 g x 5 mins) and the cell pellets 
mounted by mixing (1:1) with 4% purified agar at 50·C. After cooling 
the agar was cut into 1 mm cubes which \vere left to rinse overnight 
in washing solution. The cells \,ere then rinsed for 15 minutes in 
·veronal acetate buffer, and stained, first with osmium tetroxide 
(1% in veronal acetate buffer) for 1 hour and then with u.ranyl acetate 
(2% in verona 1 acetate buffer) for 1 hour. 
After staining, the cells were dehydrated by washing h"i th ethanol 
solutions; 25% (1 x 20 minutes), 50% (1 x 20 minutes), 75% (2 x 15 
minutes) and 100~o (2 x 15 minutes). FollO\ving dehydration the cells 
\vere embedded by immersion first with ethanol/propylene oxide (1: 1) 
for 15 minutes, then propylene oxide for 20 minutes, propylene oxide/ 
resin (1:1) for 30 minutes at 60·C, and finally resin for 60 minutes 
at 60·C. 
The agar blocks were then transferred to resin filled embedding 
capsules, and placed at the apex of the capsule cone. The capsules 
were left at 60·C overnight to allow the resin to harden. The 
mounte.d cells \vere sectioned, and sections were supported on copper 
grids, then stained with Reynold's lead citrate to increaSe contrast. 
The sections \,ere examined with an DI6B transmission electron 
microscope, at a magnification of 3000x. 
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2.3 Compounds Under Investigation 
Vernolepin and Elephantopin were, a kind gift of Dr. Sneden, 
University of Virginia, U.S.A. 
e:Y 
-,OH I I 
0 
, 
0 I Vernolepin I 
H 
0 
0 O~ 
---0 Elephantopin 
o 
Estramustine \Vas a gift of A.B. Leo, Helsingborg, SHeden. 
OH 
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ORG 4333 (llB-chloromethyloestradiol) was a gift of Organon, 
Horden, England. 
OH 
HO 
Estrolactone (1) and Estrolic acid (~) were synthesised according to 
the method described by Westcrfeld. 
HO 
HO 
o 
(1) 
OH 
COOH 
(2) 
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The following compounds 4-17 were synthesised by L.S. Chagonda 
in the Organic Chemistry Laboratory of this Department, according to 
the method of Yamada. [116] Brief analytical data is given for all 
new compounds, for further data see reference 137. 
4 3-Methoxy-16-methylene-17oxo-17a-oxa-D-homo-estra-l,3,S(10)-triene. 
o o 
mp 167-169°. [a]D + 6° «0.01). ~IS 312. 1725 (M, C20 H24 03), 
ca1c M, 312, 1725. 
Anal CZO HZ4 0 3 : ca1c%: C,76.89; H, 7.74 
Found: 76.50; 7.90 
5 3-Acetoxy-16-methylene-17-oxo-17a-oxa-D-homo-estra-l, 3,5 (10) -triene. 
o o 
AeO 
m.p. 167-170°. [a]D = ° (c, 0.02). (M,C21 H24 04), calc M 340. 1675; 
298. 1586 (M-C2H20, CI9 H22 03) ca1c 298. 1569. 
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6 3-Hydroxy-16-methy1ene-17-oxo-17a-oxa-D-homo-estra-1,3.5(10)-triene. 
o o 
HO 
m.p. 226-230°. MS 298.1567 (M C19H2203) ca1c. M 298.1569 (BP) 
7 3 -~lethoxy-17 -oxo-17a-oxa-D-homo -estra-1, 3,5 (10) -triene. 
m.p. 167-172°. MS 300.1724 (~I C19H2403), ca1c. M 300.1726. 
8 3-Acetoxy-17-oxo-17a-oxa-D-homo-estra-1,3,5(10)-triene. 
o 
AeO 
m.p. 156-60° (literature 149-151). 
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9 3-Hydroxy-17-oxo-17a-oxa-D-homo-estra-1,3,5(10)-triene. 
o 0 
HO 
10 3-MethoxY-16-methyl-17-oxo-17a-oxa-D-homo-estra-1,3,5(10)-triene. 
o '0 
m.p. 147-150°. MS 314.1882 (M CzoHZ603) ca1c. M 314.1881. 
11 3-MethoxY-16-(hydroxymethy1ene)-17-oxo-17a-oxa-D-homo-estra-
1,3,5(10)-triene. 
o 
m.p. 242-245°. MS 328.1674 (M C20H2403), ca1c. M 328.1675. 
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12 3-Methoxy-16-propy1idene-17-oxo-17a-oxa-O-homo-estra-1,3,5(10)-
triene. 
o o 
m.p. 176-179°, [a]O + 30° (C, 0.01). MS 340.2039 (~I C22H2S03), ca1c. 
M 340.2039. 
13 3-Acetoxy-16-(acetoxymethy1ene)-17a-oxo-17a-oxa-estra-1,3,5(10)-
triene. 
o o 
Ac OAc 
m.p. 215-218°. 
14 3-Hydroxy-16-(Hydroxmethy1ene)-17-oxo-17a-oxa-D-homo-estra-
1,3,5(10)-triene. 
o 0 
OH 
HO 
m.p. 262-265°. MS 314.1519 (M C19H2204) ca1c. M 314.1518. 
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15 3-Methoxy-16-(phenY1thiomethy1)-17-oxo-17a-oxa-D-homo-estra-
1,3,S(10)-triene. 
o o 
s 
Oil. MS 422.1929 (M C~6H30S03), ca1c. M 422.1916. 
16 3S-AcetoxY-16-benzYl-17-oxo-17a-oxa-D-homo-Sa-androstane. 
o o 
AeO 
m.p. 132-138°. MS 438.2771, (M C2SH3S04), ca1c. M 438.2770. 
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16a 3S-Hydroxy-16-benzYlidene-17-oxo-17a-oxa-O-homo-Sa-androstane 
HO 
m.p. 120-122° [a]O-128° CC, 0.01). MS 394.2S04 CM C26H3,,03), calc. M 394.2S08 
17 3S-AcetoxY-16-benzylidene-17-oxo-17a-oxa-O-homo-Sa-androstane. 
AeO 
m.p. 200-202°. [a]O _88° CC 0.01). ~tS 436.2622 Ut CZSH360,,), 
calc. M 436~2617. 
Found 76.S0; 7.90 
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Compounds ~-20 were synthesised by G. Edge in the Organic Chemistry 
Laboratory of this department according to the method described by 
Oh1er [86,117]. 
18. 4-(3-hydroxyoestra-1,3,S(10)-triene-17-on-16-y1)-2-methy1ene-4-
butanolide. 
HO 
m.p. 226-228°C, MS 366.1840 (MIC23H2604) 
Anal (C231I2604): ca1c%: C,7S.4%, H,7.3% 
Found: C,7S.1, H,7.1 
19. 4-(3-methoxyoestra-1,3,4(10)-triene-17-on-16-yl)-2-methylene-4-
butane lide. 
m.p. 173-174, MS 380.1988 (MIC24112S04) 
Anal (C24112S04): calc: C,7S.8%, 11,7.4% 
Found: C,7S.9, 11,7.1 
o 
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20. 3,17S-dihydroxy-4'-methylene-3'-oxo-oestra-l,3,4(10)-triene-16-
spiro-2'-oxolane. 
OH 
HO 
m.p. 213-215°C, MS 354 (MIC22H2404) 
Anal (C22H2404): calc%: C,74.6%, H,7.3% 
Found: C,74.4, H,7.5 
Compounds 21a and 21b "ere synthesised by J. C. Gill in the Organic 
Chemistry Laboratory of this department. 
21a. (20R) 3,17S-dihydroxy-20,21-epoxy-19-norpregna-l,3,5(lO)-triene 
HO 
m.p. 154-158°C, [CL]D + 41.8°, Cc, 1.0). MS 314.1880. (MIC20H2603) 
Anal CC20H2603): calc%: C,76.4%, H,8.3% 
Found: C,76.5, H,8.4 
/' 
75 
2lb (20S) 3, 17S-dihydroxy-20, 21-epoxy-19-.norpregna-1, 3,5 (10) -triene 
HO 
m.p. 184-2000 C, [a]D + 46.6°, (C, 0.9), MS 314.1876 (M1C20H2603) 
Anal (C20H2604): ca1c%: C,76.4%, H,8.3% 
Found: C,76.S, H,8.4 
76 
3. RESULTS 
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3.1 The Assay Systems 
3.1.1 Cytotoxicity 
(a) HeLa S3 cells 
The HeLa S3 line was used to evaluate the general cytostatic 
activity and cytotoxicity of compounds. The population doubling time 
of this cell line is approximately 24 hours (Figure 3.1). 
The sesquiterpene compounds elephantopin and vernolepin were 
found to have 1Cso values of the same order as those previously 
reported. [37,43] (Figure 3.2) These compounds were used as standard 
non-selective a-methylene lactones for comparison purposes. 
(b) MCF-7 and GH3 
The population doubling time of ~ICF-7 cells is reported as 
approximately 36 hours in stripped serum. [118]. The GH3 cell line 
has a population doubling time of approximately 33 hours (Figure .3.1). 
Unlike the HeLa S3 line, both cell lines have measurable levels of 
functioning oestrogen receptors. [109, 119] Only the MCF-7 line is growth 
responsive to oestrogens however. [118] 
Vernolepin exhibits a similar degree of cytostatic activity toward 
GH3 cells as against HeLa S3, (Figure 3.3). TIle 1Cso value obtained 
for elephantopin against MCF-7 cells, (Figure 3.4) is approximately 
tenfold that obtained against the HeLa S3 line. The modified assay 
procedure used with the MCF-7 cell line with greater numbers of 
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innoculum cells, may be responsible for the higher ICso value 
obtained. 
3.1.2 Receptor-Binding Assays 
Binding assays using rat uterine and GH3 cytosols gave results 
for standard compounds which compared well with literature values. [120,121] 
Oestradiol and DES were found to have EDso values for [3H]-oestradiol 
displacement close to values previously quoted for this assay 
system, (Figure 3 .. 5). 
The above assay methods were used to evaluate candidate compounds 
following the scheme: 
Cytotoxicity toward HeLa --+ receptor binding --+ 
cytotoxicity towards GH3 and/or MCF-7 cells. 
100 
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Figure 3.5. Displacement of [3Hl-oestradiol (7 n~J) from rat uterine 
cytosols by diethylstilboestrol (t) and oestradiol (0) 
~Ieans of 3 determinations. Standard errors less than 
symbol size. 
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3.2 Cytotoxicity Studies 
3.2.1 D-ring-a-methylene-o-lactone oestrogens 
The compounds examined (Figure 3.6) were as described 
in section 2.3. The D-ring-a-methylene-o-lactone compounds !, 5 
and 6 have IC50 values against HeLa S3 cells in the same range as 
elephantopin, but lower than the nitrogen mustard compound 
estramustine. (Figure 3.7, Table 3.1). 
The importance of the a-methylene-o-lactone function to 
cytotoxicity was investigated using a series of D-ring lactones and 
derivatives. Values obtained are given in Table 3.1. The 
corresponding lactones of !, ~ and ~, that is compounds ~, 8 and 9 
(estrolactone) have greatly reduced activity. Similarly substitu-
tion of the a-methylene group, as in compounds 10, !.!:., g, ~ and ~. 
also reduces cytotoxicity. On the other hand, the thiophenol adduct 
of ±, compound ~,retains considerable activity, (Figure 3.8). 
The saturated A-ring compounds such as ~, l6a and 17 are 
relatively non-toxic, even at higher concentrations, 20~g ml- 1 
(> fiO~M). 
Studies with certain of the D-ring-a-methylene- 0 -lactones were 
also performed using GH3 and MCF-7 cells. (Table 3.2) While 
compounds ~ and ~ were highly toxic to GH3 cells (Figure 3. 9), in 
line with the HeLa S3 cells, ~ (~ was not examined) I<as tenfold less 
active against ~lCF-7 cells, (Figure 3.10) as with the findings of 
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Figure 3.6. D-ring a-methylene lactone steroids and related 
compounds. 
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Figure 3.6. Continued ..... . 
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Table 3.1. Effect of D-ring a-methylene lactone steroids 
and related compounds on HeLa S3 growth 
Compound ICso (J.!M) a % Inhibition 
E1ephantopin O.64±O .01 
Vernolepin 3.S0±O.1O 
Estramustine 3 .39±O. 20 
4 O.74±0.02 
5 O.29±O.01 
6 1. 49±O .03 
7 48±3.5 
8 SO±2.5 
9 Estro1actone 30±1.0 
10 63±5.6 
11 27±2.7 
12 9±0 
13 22±1.0 
14 14±2.7 
15 1.9±O.07 
16 55±1 
16a 42±3.9 
17 42±1.1 
a Values are means of 3 or more determinations. 
b Values represent % inhibition of growth at 20).lg ml- 1 
(~60).lM) the highest dose tested.'means of 3 determina-
tions ± SEH 
b 
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Figure 3.8. Effect of i Co) and the thiophenol adduct 13 Ct) 
on HeLa S3 grOl"th. ~Ieans of 6 determinations ± SDI. 
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Figure 3.10. Effect of 5 on ~fCF-7 grOl'th. ~feans of .3 determinations 
± SEM. 
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e1ephantopin on this cell line. 
Consequently the influence of initial innoculum cell 
numbers on the observed activity of a cytotoxic compound was 
investigated using HeLa S3 cells, (Figure 3.11) Compound ~ was 
used at a concentration of 0.5~M. This concentration of 5 is 
sub-lethal under the standard assay conditions for HeLa S3 cells 
(c.f. Figure 3.7). 
As expected, the saturated A ring compound 16 was toxic only at 
high levels against NCF-7'cells. 
Table 3.2. Effect of D-ring~a-methylene-o-1actones and related 
compounds on GH3 and MCF-7 cell growth. 
Compound 1C50 (IlM) 
GH3 MCF-7 
5 0.28 2 .HO. 2 
6 1.4 
16 >30 
Elephantopin 5.ltO.0 
Vernolepin 5.2 
ORG 4333 >30 
3.2.2. 16-(cr-methylene-y-lactone)-substituted oestrogens. 
As a development of the work on a-methylene-lactone linked 
compounds, oestrogens containing an cr-methylene-Y-lactone function 
linked at the 16-position were investigated. The compounds examined 
are given belOl~ (Figure 3.12). 
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Figure 3.11. Effect of initial cell numbers on inhibition of HeLa 53 
growth by compound ~ (0.5 w~l). Means of 3 determinations 
± 5HI. 
Controls open bars. 
94 
0 
18. R = H 
19. R = CIl3 
RO 
OH 
o 20. 
HO 
Figure 3.12. 16-(a-methylene-y-lactone)-substituted oestrogens 
Compounds ~ and 20 are approximately one tenth as active 
against HeLa S3 cells as the D-ring a-methylene-o-lactone series 
(Figure 3.13, Table 3.3). Compound ~ has much lower activity, 
and is of the same order as the inactive, substituted a-methylene-
o-lactones, i.e. >60uM. Asjmilar order of activity. is seen against 
GH3 cells (Figure 3.14, Table 3.3). 
In the ~ICF-7 cell assay, ~ has similar activity as against 
HeLu S3 and GH3 (Figure 3.15). Taking into account the effect of 
ini tial cell numbers in the ~ICF-7 assay, this would suggest that 
18 shOl.s enhanced cytotoxicity tOlmrd the oestrogen-teceptor 
-- . 
containing ~ICF-7 line. (A sample of 20 was not available for 
testing on MCF-7 cells). 
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Figure 3.13. Effect of ~ Ct) and 20 C!) on He La 53 growth. Means 
of 6 detenninations ± 5EM for 18. ~leans of duplicate 
determinations for 20. A further repeat assay of 20 
gave an 1C50 of 2.SuM. 
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Figure 3.15. Effect of 18 on MCF -7 growth. Means of 3 determinations 
± SE~I. 
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Table 3.3. 
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Effect of l6-(a-methylene-o-lactone) substituted 
oestrogens on cell growth 
Compound ICSO (IlM) 
HeLa S3 GH3 MCF7 
18 12.3±0.1 12.9 1O.4±0.4 
19a (24.6±9.4) 
20 6.0 7.5 
Elephantopin 0.64±0.1 5.1±0 
a Figure in parentheses represents % inhibition of growth 
at 2011gml-l (52.611M), mean of 3 determinations ± SEM. 
3.2.3. 17a-epoxyethano-oestrogens 
As an alternative to the Il-methylene. lactone alkylating group, 
17a-epoxyethano oestrogens were assessed for activity using the 
assay systems developed. 
Against HeLa S3 cells compounds 21a and ~lb (Figure 3.16) 
have activities of the same order as the 16-(a-methYlene-y-lactone) 
oestrogens (Figure 3.17). Isomer 21a is approximately three times 
as active as its diastereomer 21b against HeLa S3 cells. 
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Figure 3.16. l7a-Epoxyethano-oestrogens 
The activities of the compounds against GH3 cells (Figure 3.18) 
are similar to those against HeLa 53. (The epoxides were not 
available for testing against MCF-7 cells). 
Table 3.4. Effects of l7-a epoxyethano compounds on cell growth 
Compounds 1C50 (j1M) 
HeLa . GH3 
2la 6.S±1.9 5.5 
2lb l8.6±2.0 17.7 
40 
20 
o I 
1 
I 
10 
MM 
I 
100 
Figure 3.17. Effect of ~a Cl) and 2lb CA) on HeLa 53 growth. Means of 
2 or 4 determinations. Inset sho\<s initial study of effect 
of 2la and 2lb on HeLa 53 growth. ~Ieans of duplicate 
determinations. 
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Figure 3.18. Effect of Q.a CA) and Q.b Co) on GH3 gro\;th. Means of 
duplicate experiments. 
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3.3 Receptor Binding Studies 
3.3.1. D-ring a-methylene-y-lactone oestrogens 
The series of D-ring compounds ~, ~ and ~ display negligible 
receptor binding to rat uterine cytosol at 2.5~M, (Figure 3.19). 
To exclude reaction with cytosolic thiols, receptor binding of 
the compounds was reassayed in cytosol treated with bromoacetone 
dimethylacetal to remove free thiols. Treatment with bromo-
acetone dimethyl acetal reduces specific binding in cytosols by 
only 15% (Figure 3.20). Further, receptor binding of DES is 
substantially unaffected, (Figure 3.21). However receptor binding 
of ~, 5 and 6 does not increase in treated cytosol, (Figure 3.22). 
Receptor binding of the parent lactones 7.., ~, ~ (estrolactone) 
and estrolic acid 2 was also assayed, (Figure 3.23). All of these 
compounds have a low affini tyfor uterine oestrogen receptors. 
Receptor binding of estrolactone, and estrolic acid was 
assayed in GH3 cytosol, (Figure 3.24). Both compounds exhibit 
similar lack of affinity binding in GH3 and rat uterine cytosol. 
It was of interest to note that one of the two unsaturated 
A-ring compounds ~ exhibited affinity for the oestrogen receptor, 
(Table 3.5) despite lacking a phenolic A-ring. 
The enzyme pyruvate kinase, with an allosteric binding site 
for oestrogens, was used as an alternative oestrogen-sensitive 
system. The activity of this enzyme is inhibited by oestrogens. 
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Figure 3.19. Displacement of [3Hl-oestradiol (7nM) by:!., i and ~ (2.5)lM) 
from normal uterine cytosols. ~Ieans of ~ determinations 
± SHI 
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Figure 3.20. Specific binding of [3H]-oestradiol in rat ~terine 
cytosols. 1 = control, 2 = cytosol in buffer minus 
dithiothreitol, 3 = cytosol in buffer minus 
di th iothrei tol pI us bromoacetone. ~Ieans of 3 determina-
tions ± SDI. 
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Figure 3.21. Displacement of [3Hj-oestradiol by diethylstilboestrol 
from normal (0) and bromoacetone dimeth,'lacetal 
treated (0 cytosols. Means of 6 deteminations ± SHI. 
Stan2ar2 errors less than symbol size. 
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Figure 3.22. Displacement of [3H]-oestradiol by i, ~ and ~ from 
no~al (open bars) and bromoacetone dimethylacetal 
treated (hatched bars) uterine cytosols. ~Ieans of 6 
deterr.linations ± SDI. Drul"( concentration 2.5 ]lM. 
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Figure 3.23. Displacement of [3HJ-oestradiol by estrolic acid (~, 
estrolactone (2), ?. and.!!. from uterine c)'tosols. Means 
of 3 deter::dnations ± SEM. Drug concentration 2.5 ~M. 
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Figure 3.24. Displacement of ('3H]-oestradiol by estrolic acid (~) 
and estrolactone (2) from uterine (open bars) and GH3 
(hatched bars) cytosols. Means of 3 de terminations 
± SHI. Drw,; concentration 2.S ~M. 
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Table 3.5. Displacement of [3Hj-oestradiol from rat uterine 
cytosol 
Compound 
Oestradiol 
DES 
DES 
Estramustine 
1 (Estrolactone) 
~ (Estrolic acid) 
4 
5 
6 
7 
8 
10 
16 
l6a 
17 
18 
20 
2la 
21b 
a EDS 0 (n~l) 
10.6±0.6 
5.6±0.1 
4.1±0.2c 
265±27 d 
3')00±100 
79±1l 
724±89 
% Oestradiol boundb 
57±8 
66::3 
57~-
-.;...) 
88:':7 
86:,:3 
99:':3 
100:;:0 
95=4 
100±0 
7.3±6 
100:':0 
100::0 
a ED50 values are means (3 or more de terminations ) ± S;:"l. 
b Values are 9, [!H)-oestradiol bound at 2.511~1, 3 or mo:·e 
de terminations ± SEM. 
c In bror.loacetone dimethylacetal treated cytosol. 
cl Subsequent assays shOl;ed lower affinity, (Figure 3.28). 
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The inhibition recorded for DES (Figure 3.25) compares well with 
the literature values. [122] Compounds !, ~ and ~ have no effect 
on pyruvate kinase activity at concentrations up to 100~M, 
confirming their lack of oestrogenic activity. 
3.3.2. 16-(a-methylene-y-lactone) oestrogens 
These compounds did displace [3H]oestradiol binding in rat 
uterine cytosols. Compound ~ was found to have considerably 
greater affinity for the uterine oestrogen receptors than 20 in 
initial studies, as shown in Figure 3.26. 
Further samples of ~, produced by crystallisation from the 
same mother liquor, shOl,ed much reduced receptor binding acti vi ty, 
(Figure 3.27). 
3.3.3. 17a-epoxyethano oestrogens 
These compounds were relatively potent in inhibiting the 
binding of [3H]-oestradiol to cytosols, though considerable 
difference was seen between the isomers 21a and 21b. Thus 21a 
(EDso = 79±llnM) is approximately ten times more active in the 
receptor binding assay than 21b (EDso = 724±89nM), (Figure 3.28). 
A comparison of the relative activity of all the compounds 
examined is given in Table 3.5. 
3.3.4. Irreversible Binding 
The extent to which the various derivatives irreversibly bind 
to the oestrogen receptor is given in Figure 3.29. The affinity 
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Figure 3.25. Effect of diethylstilboestrol on pyruvate kinase 
activity. Single determinations. 
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Figure 3.26. Displacement of [3111-oestradiol by .!.!!. (.) and 20 (0) from 
uterine cytosols. ~Ieans of 4 determinations ± sml. 
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Figure 3.27. Displacement of [3HJ-oestradiol by different samples 
of ]~ from uterine cytosols, means of 3 determinations 
± SHI. [1ru~ concentration 2.5 JlM. 
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Figure 3.29. Irreversible binding of ORG 4333 (30~~1), ~ (l5~~1), .?Q (l5~1 
2la (2.5~M), 2lb (l5~M). Means of 3 deterrninations ± SEM. 
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labelling reagent ORG 4333 has an activity in this system close to 
reported values., [123] The rank order of irreversible binding of 
compounds under investigation is 2la > ~ > 20 > 2lb. This is 
similar to the order of binding affinity, namely 2la > 18 > 2lb > 20. 
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3.4. Mechanisms of Action of A1ky1ating Agents 
3.4.1. Effect on thio1 levels 
(a) Electrophilic activity - reaction with glutathione 
Vernolepin is the most reactive of the compounds tested, follO\,ed 
by elephantopin, (Figure 3.30). Similar results have been reported 
for reaction of these compounds I<ith cysteine. [37] The order of 
reacti vi ty of the D-ring a-methylene-o -lactones, ~, .§.. and~, follows 
their cytotoxicity, .§..' 4 > ~, (Figure 3.31). 
Estramustine, the 16-(a-methylene-y-1actone) oestrogens ~, 19 
and 20 and the 17-epoxyethano-oestrogens 21a and 21b reacted 
slO\;ly or not at all I<ith glutathione under the assay conditions, 
(Figures 3.32 and 3.33) 
(b) Addition of Glutathione to media 
Glutatione at 1mM reduces tile effect of compound 4 on cell 
grol<th, and prevents cell death at higher doses of ~ (Figure 3.34). 
These effects are seen only at relatively high concentrations of 
glutathione, i.e. at a thousand fold excess over 4. 
(c) Effects of compounds on cellular thio1 levels 
Over 24 hours vernolepin rapidly depletes He La S3 thiols to an 
equilibrium level of approximately 70% of control for surface and 
55% for intracellular thio1s, (Figure 3.35). HOl<ever, observed 
over a shorter time scale this effect is apparently more complex. 
An initial sharp drop in thio1 levels is fo110l<ed by a recovery 
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Figure 3.33. Time course for reaction of l7~-epoxyetheno-oestrogens ~a Co 
and 2lb (1) with glutathione, control (0). ~Ieans of 2 
determinations. 1.0 ~ moles drug in 3 ml. 
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Figure 3.34. Effect of glutathione (1 mM, hatched bars) on inhibition 
of HeLa S3 growth by 1. at O.8lJM and 1.0lJM. ~leans of 3 
deterrninations ± SHI. 
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Figure 3.35. Effect of vernolepin (20IJM) on cell surface (1) and 
intracellular~) thiol levels. Means of 3 deterrninations 
± SEM. 
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Figure 3.36. Effect of vernolepin C20~~1) on cell surface Cl) and 
intracellular Cl) thiol levels. Means of 3 determinations 
± SEM. 
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period to reach the equilibrium level, (Figure 3.36). A similar 
effect has been observed with vernolepin and elephantopin on P8lS 
leukaemia cells. [124] 
An incubation period of 4 hours to reach equilibrium was used 
with compounds at 10, 20 and SO~M, (Table 3.6). Ability to deplete 
thiol levels followed the same order as cytotoxicity and electro-
philic activity with glutathione, and was dose-dependent. 
Inhibition of HeLa 53 growth by CL-methylene l1l;ctone compounds 
occurs over an equally short period. Thus! reduces growth below 
control levels after 3 hours exposure, (Figure 3.37). Growth rate 
is retarded even "hen cells have been exposed to 4 for short 
periods, follOlved by its removal, (Figure 3.38). 
3.4.2. + + Effects on Na /K ATPase 
The dependence of 86Rb uptake on Na+/K+ ATPase activity is 
demonstrated by ouabain inhibition, (Figure 3.39). Accumulation of 
86Rb+ reaches equilibrium after approximately 3 hours, (Figure 3.39). 
An incubation period of 3 hours was taken, using varying 
concentrations of drugs, to produce dose/response curves for 
inhibition of 86Rb+ uptake. The sesquiterpene CL-methylene lactone 
vernolepin was active in preventing 86Rb+ accumulation, reaching a 
maximum effect after approximately 30 minutes, (Figure 3.40). Indeed, 
vernolepin and the steroidal CL-methylene-a-lactone ! were most active 
in this system, ! being approximately thre~ times as active as 
vernolepin, (Figure 3.41). The parent lactone I is relatively inactive 
affording only 25% reduction in uptake at a concentration of 100~~1, 
(Figure 3.42). 
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Table 3.6. Reduction of surface (5) and intracellular (1) thiol 
levels in HeLa 53 cells after 4 hrs exposure to 
~-methylene lactones. 
% Control Values 
! 
Compound , IO).!M 2011M SOIl~1 I 
5 I 5 I 5 I 
I 
I 
I I , 
I 
, 
Vernolepin 73±4 8S±3 ! S9±2 62±2 48±2 38±3 
Estramustine 8S±1 70±IO - - - -
4 76±S S9±7 S9±2 63±2 47±2 23±3 
-
7 - - 94±S SIB - -
-
IS - - 94±S SS±3 112±4 127±1 
-
IS - - S5±3 90±2 - -
-
20 - - 6S±3 90±3 - -
-
2la - - Sl±S 87±1 I - -
, 
-
, 
I 
I 
Dashes represent not tested. 
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Figure 3.38. Effect of short exposure to compound 4 
(0.8 and 0.96 )JM), followed by removal, on 
growth of HeLa $3 cells. Means of dup li ca te 
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Figure 3.39. Uptake of 86Rb + by lIeLa S3 cells, in the absence Ce ) 
and presence Co) of ouabain CO.6 mM). Means of 3 
de terminations ± SE~I. 
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Figure 3.40. Uptake of 86 Rb+ by lIeLa S3 cells, in the absence (0) 
and presence (0) of vernolcpin (10011~1). ~Icans of 
3 determinations ± SEM. 
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Figure 3.41. Effect of vernolepin Cl) and~. Ct) on 86 Rb + uptake 
by HeLa S3 cells. Means of 3 deterrninations ± SH1. 
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Figure 3.42. Comparison of effect of ! Ct) and its parent lactone 2 CA) 
on 86Rb + uptake by HeLa S3 cells. Means of 3 determina-
tions ± SEM. 
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Figure 3.43. Effect of ~a CA) and estramustine Cl) on 8 6Rb + 
uptake by HeLa 53 cells. Means of 3 determinations 
± 5EM. 
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Estramustine and the epoxide compound 2la have much lower 
activity than vernolepin and!, (Figure 3.43). EDso values for the 
compounds are given in Table 3.7. 
Table 3.7. EDso values for inhibition of 86Rb+ uptake by HeLa S3 
cells. 
Compound EDso (IlM) 
Vernolepin 40.3±4.4 
Estramustine "'100 
4 l2.2±0.2 
-
7 >100 
-
2la >100 
-
Inhibition of the isolated enzyme by vernolepin follows a time-
course similar to the effect on 86Rb+ uptake, (Figure 3.44). A one 
hour pre-incubation with drugs was used to determine the relative 
activities of compounds, given in Table 3.B. 
10 
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Figure 3.44. Effect of vernolepin (lOOuM) on Na+/K+ ATPase activity 
with time. Means of 3 determinations ± SEM. 
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Table 3.8. Inhibitiona of Na+/K+ ATPase by compounds at 100uM. 
(1 hour pre-incubation). 
Compound Ouabain Ouabain HeLa S3 
Sensitive Insensitive 
Vernolepin 24±2 22±5 33±5 
4 21 30 56±3 
---
7 0 5 0 
---
N-ethylmaleimide -
I -
62 
a 
% Inhibition values are means of 3 (± s.e.m.) or two determinations. 
Dashes represent not tested. 
3.4.3. Uptake and incorporation into macromolecules of [3H]_ 
Thymidine by HeLa S3 cells. 
Inhibition of [3H]-Thymidine uptake by elephantopin reaches a 
maximum within 30 minutes, (Figure 3.45) in accord with literature 
reports. [43] The inhibition by compound! follows a similar time 
course, (Figure 3.46). Incubation periods of 30 minutes with drug 
were used to produce dose/inhibition curves of [3H]-Thymidine uptake. 
The inhibition observed with elephantopin is similar to that 
recorded elsewhere, (Figure 3.47).[43] Estramustine is relatively 
inactive, (Figure 3.48). Compound !is the most active of the 
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Figure 3.45. Uptake of [3llj-Thymidine by HeLa 53 cells in the absence C.) 
and presence C') of elephantopin (lOOllM). Means of duplicate 
resul ts. 
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Figure 3.46. Uptake of [311]-TIlymidine by BeLa 53 cells in the absence Cl) 
and presence Cl) of :!. ClOOI1~I). ~Ieans of duplicate results. 
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Figure 3.47. Effect of elephantopin on [3HJ-Thymidine uptake by 
HeLa S3 cells. Means of 3 determinations ± SEM. 
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Figure 3.48. Effect of estramustine on [31I] ~Thyr.Jidine uptake by 
HeLa S3 cells. Means of 3 determinations ± SEM. 
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alkylating compounds tested, with approximately ten-fold the 
activity of elephantopin, (Figure 3.49). While the thiophenol 
adduct of i, compound ~ is also considerably more active than 
elephantopin, (Figure 3.50). 
Testing of the lactone ~, to eliminate the possibility of 
inhibition due to the steroid nucleus itself, revealed activity 
similar to that of~, (Figure 3.51). The activities of oestradiol 
and diethylstilboestrol, (Figure 3.52) confirmed this 
finding. Unrelated compounds such as benzocaine, dexamethazone and 
progesterone were also found to have activity in thiss75tem, 
(Figure 3.53, 3.54 and 3.55). The time cOllrseof inhibition by 
dexamethasone is similar to that of elephantopin and i, (Figure 3.56). 
rcs 0 values for the compounds are given below in Table 3.9. 
Table 3.9. rcso values for inhibition of [3Hj-Thymidine uptake. 
Compound rcso (IlM) a 
Elephantopin 39.l±2.3 
Estramustine >100 
Dexamethazone 2s.4±5.8 
Progesterone 6.6b 
Oestradiol s.6±0.3 
D.E.S. 3.3±0.2 
Benzocaine 7.sb 
4 4.0±l.0 
7 l4.l±4.0 
15 l7.3±l.0 
a Values are means (4 or more determinations) ± SEM. b Figures are 
means of 2 determinations. D.E.S. = diethylstilboestrol 
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Figure 3.49. Effect of ~. on [3H]-Thymidine uptake by HeLa 53 cells. 
Means of 6 determinations ± 5EM. 
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Figure 3.50. Effect of 15 on [3111-Thymidine uptake by lIeLa S3 cells. 
Means of 6 determinations'± SEM. 
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Figure 3.51, Effect of 7 on [311]_ Thymidine uptake by HeLa 53 cells. 
Means of 6 determinations ± 5EM. 
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Effect of oestradiol and diethylstilboestrol on [3Hj-Thymidin 
uptake by HeLa 53 cells. Means of 3 determinations ± 5EM. 
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Figure 3.53. Effect of benzocaine on [31l1-Thymidine uptake by 
lleLa S3 cells. Single determinations. 
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Figure 3.54. Effect of dexamethasone on [3I1j-Thymidine uptake. 
Means of 6 determinations ± SHI. 
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Figure 3.55. Effect of progesterone on [3Hl-Thymidine uptake. Single 
determinations. 
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Figure 3.56. Uptake of [3Hj-ll1ymidine by BeLa S3 cells in the absence C') 
and presence Cl) of dexamethasone ClOll~I). Values represent 
± SEM. n = 3 
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Inhibition of [3Hj-Thymidine incorporation was apparent only at 
-high concentrations of elephantopin and!, (Figures 3.57 and 3.58). 
Dexamethazone did not inhibit [3Hj-Thymidine incorporation at doses 
up to 200~M. This compound is reported to inhibit incorporation at 
concentrations belOl, l~M, using a different assay system, however. 
[125j 
IC50 values for inhibition of [3Hj-Thymidine incorporation into 
macromolecules are given below in Table 3.10. 
Table 3.10. IC50 values for inhibition of [3Hj-Thymidine incorpora-
a 
tion. 
Compound 
Elephantopin 
4 
Dexamethazone 
a IC50 (~M) 
67.7±2. 
77 .7±7 
»200 
Values are means (3 or more determinations) ± SEM. 
3.4.4. Inhibition of mitochondrial respirations and effects on 
Lysosomal membrane stability. 
Elephantopin and! inhibit state 3 respiration of rat liver 
homogenates, at 100~M, (Table 3.11). State 4 respiration is largely 
unaffected at this dose. Oestradiol causes inhibition of approximately 
the same degree. 
Pre-incubation of homogenate with Elephantopin and! for 
2 hours at 4°C did not greatly increase the extent of inhibition, 
(Table 3.11). 
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Figure 3.57. Effect of elephantopin on [3H]-Thymidine incorporation 
into acid insoluble material by HeLa S3 cells. Means 
of determinations ± SHI. n = 4. 
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Fi~lre 3.58. Effect of i on [3Hj-Thymidine incorporation into acid 
insoluble material by HeLa S3 cells. ~leans of 4 
determinations ± SDI. 
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Table 3.11. Inhibition of rat liver mitochondrial respiration by 
a 
compounds at 100~M . 
Compound % Control 
State 4 State 3 
Elephantopin 9S.9±7.S (102.B±0.5) 7l.9±6.2 (60.6±5.2) 
Oestradiol 101. 2±4.4 75.2±1.6 
4 111.9±7.S ( BO.B±9.0) 65.9±1.2 (56.2±1.0) 
a 
values represent means (3 determinations) ± SEM. Figures 
in parentheses are results obtained after 2 hour pre-incubation 
periods at 4°C. Control values for oxygen consumption were 
4S.S±2.0, and 2l0.7±B.0 n atoms 0 minute- 1 for state 4 and 
state 3 respiration respectively. 
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Cells treated wi th ~, examined by scanning and· transmission 
electron microscopy, exhibit contraction of cytoplasm, as shown in 
Figures 3. 59a and 3.59b. Compound ~ produces progressive 
v~cuolation and disintegration of the cytoplasm, while the nucleus 
appears relatively intact, (Figures 3.60 a-d). Production of 
vacuoles was apparent in all cells treated with !, but not those 
treated with elephantopin. The possibility that 4 destabilises 
lysosomal membranes, releasing hydrolase enzymes was investigated 
using rat liver microsomal preparations. 
Compound ~ destabilises rat liver lysosomes to-a considerable 
extent, (Figure 3.61). The lactone ~ in contrast, stabilises the 
lysosomal preparation. The sesquiterpene compounds, elephantopin 
and vernolepin stabilise lysosomal membranes, in line with previous 
reports. [59] 
Compound ~ does not affect the activity of the lysosomal 
marker enzyme aryl sulphatase, (Figure 3.62). Elephantopin and 
vernolepin inhib:i,t this enzyme slightly as previously reported, as does 
the lactone 7. 
3.4.5 Cytotoxicity Towards Microorganisms 
Estramustine, elephantopin and the a-methylene lactone 4 did not 
inhibit the growth of Escherichia coli, Penicillium crysogenum or Candida 
albicans at concentrations up to 50~g.ml-l (i.e. > lO~M). These results 
are in accord with those reported for sesquiterpene compounds against 
Staphylococcus aureus and Bacillus subtilis where minimal inhibitory 
concentration values of 25-100~g.ml-l were recorded. [61] 
Figure 3.59. 
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Scanning electron micrographs of untreated cells (a), 
and cells treated with 4 at 1.0 ~M for 24 hours Cb). 
Figure 3.60 a-d. 
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156 
--,--
.-~ ~ "'~-~-.,..,..-.., 
b i 
Transmission electron micrographs of cells 
from the same sample treated with 4 (1.0 uM) 
for 24 hours. 
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Figure 3.60 continued. 
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Figure 3.61. Effect of steroidal and sesquiterpene a-methylene lactones 
on release of the lysosomal enzyme aryl sulphatase. 
Results are expressed as percentage values of enzyme 
released from triton X-lOO treated liver cytosol. Means 
of' 6 determinations ± SEM. El = elephantopin, Ver = 
vernolepin. Compounds at 100 llM. 
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Figure 3.62. Effect of steroidal and sesquiterpene lac tones on aryl 
sulphatase activity. Results expressed as percentage 
of control activity in triton X-lOO treated liver 
cytosols. Means of 3 de terminations ± SEM. El = 
elephantopin, Ver = vernolepin. Compounds at 100 ~M. 
160 
4. DISCUSSION 
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4.1 Steroidal Alkylating Agents Selectively Toxic to 
Oestrogen-Responsive Tumours: The Assay Systems 
The assay procedures employed were designed to detect compounds 
which exhibit selectivity of action towards oestrogen responsive 
tumours. Initially, cytotoxicity was determined using the HeLa S3 
cell line. Selectivity of action was assessed from two in vitro 
assays; 1) Receptor binding to oestrogen receptors in the rat 
uterine cytosols, and 2) Cytotoxicity against cell-lines having 
oestrogen receptors. 
4.1.1 Cytotoxicity: 
HeLa 53 cells I,ere used to assess cytotoxicity, as the bio-
chemistry of this cell line has been studied extensively. [126,127] 
The cells are susceptible to the a-methylene lactone containing 
elephantopin and vernolepin and indeed have previously been used to 
test the cytotoxicity of sesquiterpene a-methylene lactones. [43] 
The Cancer Chemotherapy National Service Cent er (CCNSC) protocol to 
assess cytotoxicity was followed. The drug contact time, of 48 hours, 
is approximately twice the cell cycle time of HeLa S3 cells. Any drug 
effect specific for a particular phase of the cell-cycle I,ill thus 
be allowed expression. 
The HeLD. S3 system should only detect general cytotoxicity, not 
potential selecti vi ty. Results indicate that HeLa S3 ce lIs nei ther 
contain oestrogen receptors, nor respond t.o oestrogens in the grm,th 
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medium, confirming previous work. The HeLa S3 line has been reported 
to contain glucocorticoid receptors, but not oestrogen receptors. 
[125] 
Some use of the MCF-7 (human breast cancer) and GH3 (rat pituitary 
tumour), oestrogen receptor bearing cell lines was made. These cells 
allow the study of oestrogens and anti-oestrogens. The MCF-7 cell 
line is one of the best in vitro model systems of an' oestrogen~ 
responsive mammary carcinoma presently available. [105, 128] This cell 
line is employed by a number of groups investigating cytotoxic-
linked oestrogens. [93,129] Oestrogen receptors have been identified 
and characterised, and importantly the receptor mechanism is functional. 
[128] Growth of ~ICF-7 cells is reported to be stinulated bv the 
presence of oestrogens but inhibited by anti-oestrogens. [105,118] 
Progesterone receptors have also been identified and are oestrogen 
induceable. [105,128] 
However, the MCF-7 line contains human RNA tumour virus particles. 
[130] This meant it could not be routinely used in our laboratories. 
Some experiments were performed by the author during a visit to I.C.I. 
Pharmaceuticals Divisions, Alderley Park. A modified assay, using 
greater numbers of cells in the initial innoculum was employed. This 
resulted in higher ICso values, thus the ICso for elephantopin against 
MCF-7 was approximately 5-10 x that obtained against HeLa S3. The 
effect of changes in innoculum number of cells was confirmed using 
HeLa S3 cells. From the result it is apparent that initial cell 
number in the assay has a critical effect 6n the ICso value. 
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Increasing cell numbers produces a corresponding increase in the 
level of drug required for cytostatic activity. Account of this 
effect must therefore be taken in evaluating the results of the 
MCF-7 assay. 
As an alternative the GH3 line was used. Growth of these cells 
was inhibited by e1ephantopin and vernolepin with the same potency 
as shown towards HeLa S3. However, assays using GH3 cells employed 
a longer drug contact time, taking account of their slower growth 
rate. Like the MCF-7 cell the GH3 cell contains functional oestrogen 
receptors as evidenced by the oestrogen-induced synthesis of prolactin 
and of progesterone receptors. [109] However, unlike MCF-7 cells 
growth of this line is not stimulated by oestrogens. [109] On the 
other hand GH3 cells will concentrate oestradiol. from medium 
supplemented with the [3H]-labelled hormone. [77] 
Although the majority of the cytotoxicity studies were performed 
on HeLa S3 cells,use was made of the oestrogen receptor containing 
lines. This gave a cross section of in vitro model systems. If any 
selectivity is evident it might be expected to show up as differing 
activities towards the various cell types. 
4.1.2 Oestrogen receptor binding studies 
Affinity for oestrogen receptors in rat uterine cytosols was 
used as an indirect indicator of specificity in the oestrogen-
linked compounds. The assay is widely used as a model system in 
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evaluating the potential specificity of cytotoxic-linked oestrogens. [93,10C 
101] Comparison with test drugs and standard oestrogens 
is therefore possible. 
Relatively small amounts of test compound are necessary in this 
assay. In contrast testing in animal systems, such as DMBA rat 
tumours [13l],requires quantities in the gramme range. It has the 
further advantage that quantities of receptor containing cytosol 
can be prepared easily. As an alternative and for comparison, 
receptor containing cytosols from cell cultures were also used. 
However, this requires production of large numbers of cells and for 
this reason use of GH3 cell cytosols was limited. Receptor 
binding in cytosols from GH3 was assessed to determine if the 
specificity of the receptors from pituitary cells was equivalent 
to rat uterine receptors. 
One disadvantage of the receptor-binding system is that it 
does not distinguish between oestrogenic and anti-oestrogenic 
compounds. [132] Any anti-oestrogenic properties of oestrogen-linked 
drugs will not therefore be detected from this assay alone. On the 
other hand the test system does allow determination of the potential 
of the compounds for alkylating the oestrogen receptor. This 
technique is valuable for three reasons; 
1) It gives an indication of alkylating activity against cellular 
nucleophiles other than the 'model' thiol compounds, glutathiune 
and cysteine. 
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2) Information may be gained on the structure of the receptor 
binding site. 
3) It may provide information on the mode of action of the compounds 
on receptor bearing cells. 
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4.2 Cytotoxicity and Potential Selectivity of 
Steroidal Alkylating Agents 
4.2.1 D-ring steroidal ~-methylene o-lactones 
The synthesis of the D-ring lactone, estrolactone l and its 
open ring form estrolic acid 2 was first described by Westerfeld. [133] 
The biological properties of the two compounds were studied in the 
HO HO 
1 Estrolactone 2 
OH 
COOH 
estrolic acid 
course of research on the metabolism of oestrone. [134] The lactone 
1 is reported to have an oestrogenic potency one-sixteenth, and the 
acid ~ one-fifteenth, of the parent oestrone, as determined by the 
Allen/Doisy test. [134,135] The compounds apparently stimulate pituitary 
hormone secretion to a greater degree than can be accounted for by 
oestrogenic activity. [134,135] 
The activity of these compounds as oestrogens prompted us to 
synthesise and study ~-methylene-o-lactone derivatives of the 
parent lactone, [136] as potential cytotoxic oestrogens. Since 
estrolactone is oestrogenic, albeit mildly, the ~-methylene 
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derivatives might be reasonably expected to have some affinity for 
oestrogen receptors, and hence be selectively toxic towards 
receptor-bearing cells. A series of these compounds of general 
structure 3 were synthesized in the Organic Chemistry Laboratory 
of this department by L. Chagonda. [137] 
3 
It is apparent from the effects of the compounds on HeLa 53 
growth that the ~-methylene-lactone function plays an integral role 
in their cytotoxic activity. Thus the compounds ±! ~ and 6 with 
activity in the 1 ~M range have greatly increased activity over 
o 
Ra 
o 
4 R = CH3 
5 R = Ac 
6 R = H 
7 RI = CH3, R2 = H 
8 RI = Ac, R2 = H 
9 RI = H, R2 = H 
R10 
10 RI = CH3, R2 = CH3 
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their parent lactones ?, ~_ and!!. which require in excess of 20 ~~1 
for activity. Furthermore compound 10, the a-methyl analogue of 
~, has one-nineteenth the activity of the a-methylene compound ~. 
The necessity of the a-methylene lactone group in cytotoxic activity 
is well documented. [37] Thus of two A-ring cholesterol derivatives 
(Fig. 4.1) only b is cytotoxic. [87] Sesquiterpene compounds show a 
o o o 
(a) (b) 
Figure 4.1 
similar dependence on the presence of an a-methylene lactone 
function for cytotoxicity. [37] Reduction of elephantopin to 
tetrahydroelephantopin or hexahydroelephantopin, results in loss 
of acti vi ty. [37] 
o 
0>--< 
--0 
o 
Elephantopin 
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Tetrahydroelephantopin 
Hexahydroelephantopin 
o 
The importance of the a-methylene lactone group is further 
underlined by the markedly reduced activity observed in those 
compounds in which the methylene group is substituted. Compounds 
~, ~, ~, and ~ are only weakly cytotoxic relative to the 
unsubstituted compounds !, ~, and~. Steric and/or electronic 
effects may be responsible for the lack of activity of the 
o 
11 Ri = CH3 R2 = OH 
12 Ri = CH3 R2 = C2115 
13 Ri = Ac R2 = oAc 
14 Ri = H R2 = OH 
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substituted compounds. This effect has also been observed in a 
series of alkoxy-substituted a-methylene-Y-lactones. [46] 
An apparent anomoly is the thiophenol adduct, 15. This 
compound exhibits considerable cytotoxic activity, having 
approximately half the activity of the parent compound ~.' The 
reasons for this are obscure. The compound may have activity in 
15 o 
its own right. Alternatively it may undergo metabolic conversion 
in the cells to regenerate the free methylene function. This 
conversion might be possible by sulphoxidation and elimination or 
S-dealkylation followed by elimination, [138] such as occurs with 
compounds like azathioprin. [138] Enzyme systems capable of both 
conversions have been characterised. [138] Regeneration of the 
a-methylene group may release thiophenol, which is itself cytotoxic. [139] 
Another possibility is that the thiophenol adduct might undergo an 
exchange reaction with a more nucleophilic thiol group, such as might 
be found in the active site of enzymes. [140] Exchange reactions 
with essential thiols would have the same end result as the Michael 
addition in alkylating these thiols. 
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The 1Cso values obtained for vernolepin and elephantopin on 
HeLa S3 cells agree closely with literature values for activities 
on these and other cell lines. [37,43] The steroidal compounds tested 
have activities in the same range as these standard compounds but 
are more active than the drug estramustine which is used in 
OH 
Estramustine 
treatment of prostate cancer [141] 
The steroidal compounds seem sufficiently cytotoxic to exhibit 
anti-tumour activity and therefore fulfil one of the criteria 
necessary for a useful anti-cancer agent. 
On the other hand, oestrogen-receptor binding results with the D-rin 
compounds proved disappointing. 'TIle most cytotoxic compound, the 3-
acetoxy deri vati ve~, had an affinity for the oestrogen receptor approx-
imately one-thousand times less than that of the synthetic oestrogen, 
DES. DES \~as found to have an EDsO of approximately 5 n~1 in displacing 
[3H]-oestradiol from the receptor, in agreement 1<i th other reports. 
[120,121] 
H 
Diethylstilboestrol (DES) 
HO 
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Poor receptor affinity in 4 and 5 was not unexpected since a 
- -
3-hydroxyl function is believed to be necessary for binding. [142,143] 
The poor binding observed Idth the 3-hydroxy compound, ~, was 
unexpected. It was felt that the poor binding properties could be due t 
reaction of the c<>-methylene functIon with thiols present in the 
cytosol, thereby preventing access to the binding sites. The 
uterine cytosols were found to contain 0.2 mM thiols in addition to 
the dithiothreitol added to prevent their oxidation. This is in 
the same range as that determined by Katzenellenblgen. [101] 
To test whether cytosolic thiols were interfering, cytosols were 
treated with bromoacetone-dimethylacetal as described by 
Katzenellenbogen. [101] This removed measurable thiols but 
reduced specific binding by only 15%. In addition,the affinity of 
DES for the receptor was unaffected (EDso in treated cytosol 
4.0 nM, compared to 5.5 nl-l in untreated cytosols). 
Treatment of cytosols with bromoacetone-dimethylacetal did not 
significantly improve the receptor binding of the 3-hydroxy-
analogue §... The lack of binding observed for this compound must 
therefore be caused by the D-ring lactone structure. This view was 
supported by experiments which demonstrated the poor receptor binding 
of estrolactone 1 and estrolic acid ~~ although as discussed previously 
these compounds are oestrogenic. 
Estrolic acid ~ has greater oestrogenic potency than the lactone 
1. [132,133] HOI;ever, this difference in oestrogenic potency is not due 
to enhanced receptor affinity, c.f. Figu~e 3.24. Of course the binding 
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assay only measures affinity for the receptor and not efficacy 
Possibly the difference is due to the ability of the estrolic 
acid-receptor complex to induce an oestrogenic response in target 
cells. The greater effect observed on pituitary secretion of 
estrolic acid and estrolactone is apparently not caused by 
preferential binding to pituitary receptors. As evidenced from 
binding studies to GH3 cell recep<tors .. 
The relatively poor binding affinity of the D-ring compounds is 
reflected in their lack of selectivity against oestrogen receptor 
bearing cell lines. The ICso values for cytostatic activity against 
the oestrogen receptor bearing GH3 cells are in the same range as 
those for the HeLa 53 line. The compounds also have comparable 
activities relative to each other on GH3 cells indicating a common 
mode of action on the two cell lines. 
A similar result was observed with the MCF-7, mammary carcinoma 
cell line. The steroid compounds shOl,ed no better activity than 
the unselective elephantopin. Dose/response curves against the 
MCF-7 cells were shifted to the right relative to those for HeLa 53 
and GJl3 cells. However, this was as a result of the slightly 
different assay protocol used, i.e. increased numbers of cells. 
Three types of interaction with the receptor are involved in 
oestrogen binding; [142] 
1) Hydrogen bonding with the terminal oxygen groups. 
2) IT-complex formation with the aromatic A-ring. 
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3) Hydrophobic interactions with the steroid skeleton, which are 
believed to be the most influential on receptor binding. 
The low receptor affinity observed for the D-ring lactone 
compounds is probably as a result of the disruption of these 
interactions. In order to progress with this series of compounds 
we need to know how closely they fit the criteria for oestrogen 
receptor activation. 
A very important property of oestrogenic molecules is the 
distance bet\,een the terminal oxygens. In DES the terminal oxygens 
are 12.IA apart. DES has a slightly higher affinity for the oestrogen 
receptor than oestradiol in which the oxygens are lO.9A apart. The 
17 OH of oestradiol is believed to hydrogen bond a molecule of water 
during receptor binding. [144] This increases the distance between 
terminal oxygens from 10.9 to l2.1A, as for DES. The distance 
between the terminal oxygens of the D-ring compounds is similar to 
that for DES. (Figure 4.2) 
It is thus apparent that simple intramolecular distance between 
terminal oxygen groups is not sufficient to provide compounds 
recognisable to the receptor. Other factors must be considered. Thus 
the carbonyl oxygens of D-ring lactones cannot hydrogen bond to 
the same extent as a hydroxyl group, since they act only as hydrogen 
acceptors. This is shown also with oestrone, which binds to a lesser 
degree than oestradiol. [143] The orientation of the terminal oxygen 
functions is important. [145,146] l7cx-oest;radiol has only one tenth 
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Estrolactone 
Estrolactone 
DES 
Figure 4.2. ~lolecular models of estrolactone and diethylstilboestrol 
(DES) showing similarities between intramolecular 
distance and positioning of terminal oxygens. 
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the binding affinity of the 17 S-isomer. [142] Reduced hydrogen 
bonding at the 3-position would also occur in the 3-substituted 
compounds ~. and ~ and their corresponding lactones 7 and S. The 
importance of a free 3-0H is confirmed by the weak binding of 
3-methoxyoestradiol compared'with oestradiol itself. [143] 
Hydrogen bonding of the 3-hydroxyl grouping in ~, estrolactone 
and estrolic acid may also be affected by their D-ring structures. 
The 3-hydroxyl of oestrone is more acidic than that of oestradiol 
by 0.10 pK units. [144] This is believed to be' causeJ by the long 
range electrophilic effect of the l7-keto group. [144] As a result 
the 3-hydroxyl of oestrone acts only as a hydrogen donor, while that 
of oestradiol acts as both donor and acceptor. [144] 
Obviously changes in the overall conformation of the steroid 
will affect the relative positions of the oxygens, and so affect 
their binding. Similarly effects on hydrophobic bonding and rr-complex 
formation will occur when there is a change in the molecular 
conformation. Introduction of the lactone group into the D-ring 
may cause an alteration in this overall conformation of the steroid 
via conformational transmission. [144,145] In '.the two natural oestrogens 
oestradiol and oestrone, the commonest form has the B-ring in the 
7a, SS-half chair conformation. [144] In this structure the C(9) , 
C(lO), C(5) and C(6) atoms are in the same plane. [144] The overall 
effect is to produce a molecule which is almost planar between the 
A and Brings, [144,146], Figure 4.3. Disruption of this conformation may 
reduce both hydrogen bonding of the 3-hydroxyl and rr-complex formation 
Figure 4.3. 
177 
HO 
o 17-OH 
Bay regions of oestradiol where substitution may 
alter conformation, and the conformation of the 
oestradiol molecule. 
with the A ring, as well as hydrophohic interactions with the 
other rings. Exocyclic interactions bet\;een rings, particularly in 
the Ale and BID bay regions, profoundly affects the overall steroid 
conformation. [144,145] 
It is worth noting that of the D-ring structures tested,only 
one compound, ~ displayed receptor affinity, displac~ng 100% of 
.0 o 
o 
Ac 
16 17 
[3H] oestradiol at 2 ,5 1l~1. This compound .lacked an exocyclic 
a,S-unsaturated group and was therefore non-toxic against HeLa S3. 
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Furthermore it had no demonstrable oestrogenic properties when 
assayed on MCF-7 cells. Over the range of doses used it neither 
inhibited nor stimulated MCF-7 growth, in medium devoid of oestrogen. 
The position of the phenyl ring would seem important for receptor 
affinity since the unsaturated derivative ~ displayed no receptor 
binding activity at 2.5 ~M. This compound was also inactive in 
cytotoxicity assays against HeLa S3 cells. It will be interesting 
to determine why ~ should have oestrogen receptor affinity. 
From the results it is clear that introductio~ -of an a-methylene 
lactone group into one of the oestrogen rings is counter-productive. 
The function produces too great a disruption of the oestrogen 
structure thereby causing a loss of receptor binding activity and 
hence of potential selectivity. 
Accordingly it was necessary to determine if the a-methylene 
lactone function could be attached to oestrogens via an exocyclic 
linkage without serious reduction of receptor binding affinity. 
Exocyclic linking of a-methylene-y-lactones to steroids has been 
reported previously. [86] This involved reaction of ethyl 
a-(bromomethyl) acrylate with the appropriate steroidal ketone, 
in this case cholesterol derivatives, by a Reformatsky-type reaction. 
For our purposes, however, the choice of the position on the oestrogen 
molecule for substitution was constrained by effects on receptor 
binding and by the chemistry of the reaction. 
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4.2.2 l6-(~-methylene-y-lactone) substituted oestrogen derivatives 
The substitution of cytotoxic" groups on the oestrogen skeleton 
affects receptor affinity in two ways: through effects on the 
hydrophobic character of the molecule and by steric hindrance. The 
cytotoxic group should be as lipophilic as possible. [141] The 
oestrogen receptor binding site is strongly lipophilic, [141] and 
additions of polar substituents,especially to the Band C rings are 
poorly tolerated, [143] although polar groups are tolerated to a 
greater degree in the D-ring, at the 16 position. [143] 
Steric hindrance causes a reduction in oestrogen receptor 
affini ty because of the strain it exerts on the receptor protein 
during binding. [142] Binding of oestrogens to their receptor is 
not by a simple diffusion process of the oestrogen into the binding 
site. [142] This is confirmed by the low association rate of the 
oestrogen-receptor complex which is much lower than would be expected 
for a diffusion dependent process. [142] It is believed that the 
binding process involves a conformational change in the receptor 
protein, to accommodate the steroid molecule. [142] The process is 
thus analogous to the induced-fit interaction of some enzymes with 
their substrates. [140] 
Mapping of those positions on oestrogens which tolerate 
substitutions has been attempted by various groups. [142] 
Derivatisation of the 3- and l7-hydroxyl groups has been well 
documented, and produces a marked reduction in binding. [142] This 
effect has been observed with the nitrogen mustard compounds such as 
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estramustine. [147] Addition of a methyl group at the 1, 2, 6a, 
lsa, 158 and 18 positions causes a significant reduction in 
HO 6 
18 OH 
17 
Figure 4.4. Positions in the oestra~iol molecule 
where methyl substitution alters affinity 
for the oestrogen receptor. 
binding, (Figure 4.4). ~Iethyl additions at the 7a, llB and l7a 
positions are better tolerated. Thus for example the steroidal 
alkylator ORG 4333 (llS-chloromethyloestradiol) [123,148] exhibits 
receptor affinity in the same range as oestradiol; the methyl 
substitution at the 7a-position of oestradiol affords an increase 
OH 
ORG 4333 
HO 
in receptor binding over the parent compounds. [142] This is ascribed 
to the increased lipophilicity resulting from the addition. [142] 
It was decided to synthesise and investigate the properties 
of oestrogens substituted at the l6-posi tions \~ith an a-methyl-y-lactone 
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group. 16-Substituted oestrogens do retain considerable receptor 
binding capacity. [149] Thus oestriol binds to the oestrogen receptor 
with an affinity similar to that of oestradiol. [143,149] Also a 
OH 
HO Oestriol 
series of l6-iodinated oestrogens have been produced which have 
receptor affinities in the same range as the parent oestrogens. [150] 
The synthesis of the l6-(a-methylene-y-lactone~was accomplished 
by G.J. Edge in the Organic Chemistry Laboratory of this department 
[151] 
Three compounds incorporating an a-methylene-y-lactone ring were 
synthesised, namely~, 19 and 20. The compounds were subsequently 
18 R = H 
19 R = CH3 
RO OH 
20 
HO 
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assayed for cytotoxicity against HeLa S3 cells. The 16-spiro compound 
20 proved the most cytotoxic of the three, followed by l~ and 19. 
The relatively poor activity of l2. against HeLa S3 cells is surprising, 
. since in the D-ring series the S-methoxy compound ~ .. is more active 
than the 3-hydroxy~. The observed enhancement of reactivity of 
20 over ~may'be due to interaction with the 17-0H, as with the 
hydroxyl adjacent to the methylene group seen in verno1epin. [37] 
The a-methy1ene-y-1actone compounds exhibit considerably lower 
cytotoxici ty (in region 10-20 )JM) than the D-ring a-methy1ene-
o-lactones (activi ty in range 0.1-1 ~M). 
Receptor binding activity of the two compounds with a 3-hydroxy 
function, ~ and }Q was determined. Compound 20 has a binding affinity 
in the same range as estramustine (EDso ~ 3.4 )JM). This result is 
disappointing since the compound is the nearest in structure to 
oestradiol, having a 17-hydroxyl group. The spiro group is possibly 
too bulky, and too closely associated with the steroid skeleton. 
This may affect the hydrogen bonding capacity of the 17-hydroxyl. 
Alternatively the spiro function may affect the conformation of the 
oestradiol molecule, or the group may simply be too large to be 
accommodated by the receptor binding site at that point. 
Evaluation of !~ showed significant binding, (EDso = 265 nM) 
more than tenfold that of 20 (EDs 0 = 3400 nN) . Unfortunately testing 
with different samples of ~~ revealed a binding affinity considerably 
less than that for compound 20. The samples provided were prepared 
by crystallisation on a milligramme scale trom a single mother 
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liquour. Four isomers of l~ are possible owing to chiral centres 
at Cl6 and the exocyclic carbon forming part of the lactone ring 
(Figure 4.5). 
HO 
Figure 4.5 Chiral centres at the 16 position of 
compound 18. 
Fractional crystallisation may have given rise to either different 
mixtures or different single isomers. This was not detected from 
their spectroscopic properties, but the problem is currently under 
investigation in the Organic Chemistry Laboratory. The first sample 
of ~~ produced may therefore consist mainly of the isomer which exhibits 
the better receptor-binding properties. The stereochemistry of 
substituents at the l6-position is known to be important. l6a-Iodo 
oestrogens have lower affinity for the receptor than their 
l6S isomers. [150] Similarly the l6a- and l6S-isomers of oestriol 
exhibit differences in receptor affinity, the l6S isomer having 
greater affinity. [143] 
Compounds ~ and 20 displayed no selectivity against the ER+ 
GH3 cells. Cytotoxic doses were in the same range as for HeLa S3 cells. 
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The EDso value for ~! against MCF-7 cells was similar to that for 
the HeLa S3 line. However, a sample of 20 was not available for 
testing against the MCF-7 cell line. 
Since dose-response curves for cytotoxic activity against 
MCF-7 are shifted to the right, and on comparison with results 
for elephantopin it is apparent that l! exhibits some selectivity 
for this oestrogen-responsive cell line. Thus the lCso ratio 
MCF-7/HeLa for elephantopin is ~B.O whereas forlB is ~1.0 (Table 4.1). 
This group of compounds therefore, whilst not hlghly cytotoxic, 
do seem to have the potential to provide useful drugs. HOI,ever, any 
further advances in this area must await the difficult chemical 
task of separating the various isomers. 
Table 4.1. lC
so 
ratios, MCF-7/HeLa S3, GH/HeLa S3 
Compound 
D-ring a-methylene 
lactone 5 
Elephantopin 
16-a-methylene-y-Iactone 
substi tuted, lB 
Vernolepin 
Ratio lCso v MCF-7 
lCso v HeLa S3 
7.2 
B.O 
0.85 
Ratio lCs.) v GH3 
lC::) v HeLa S3 
0.97 
LOS 
1.5 
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4.2.3 17~-Epoxyethano-compounds 
A series of oestrogen epoxide derivatives were prepared by 
J.C. Gill in the Organic Chemistry Laboratory at this Department. 
The carcinogenic properties of these compounds, as potential oestrogen 
metabolites, is currently being investigated by Dr. Grover's group 
at the Cancer Research Institute Laboratories. In addition 
to their carcinogenic properties however, these epoxides are of 
interest as 
the breast. 
possible target selective agents against cancers of 
m&y b;z 
The epoxide alkylating function. , cyto,oxic, as well 
as carcinogenic. [62] Further it is less bulky than the 
~-methylene-y-lactone functions, and might therefore disrupt 
receptor binding to a lesser degree. 
Two 17a-epoxyethano-diastereomers 21a and ~~ have been 
examined to date. The stereochemistry is assigned tentatively by 
HO HO 
2la 
Figure 4.5 
J.C. Gill on the basis of mechanistic studies 
2lb 
HO H",,£ 
, 
, 
As discussed previously, substitutions at the l7~ position are 
tolerated well. Introduction ofa methyl group at this position in 
oestradiol reduces receptor affinity by only 13%. [142] The synthetic 
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oestrogen 17~-ethinyl-oestradiol has a higher receptor binding 
activity than oestradiol. [143] The two epoxides are possible 
metabolites of ethinyloestradiol, and may retain some of the binding 
properties of the parent compounds, 
The epoxides exhibit cytostatic activity against HeLa S3 cells 
in the same range as that for the l6-(~-methylene-y-lactone) oestrogens, 
but lower than that for the D-ring compounds. The epoxides are also 
cytotoxic since at higher doses they red1lce cell numbers below 
inocculum levels. Isomer ~ c.rC 5 0 '" 6.5 IJM) is approximately three 
times as active against HeLa S3 cells as £. (IC50'" 18.6 IJM). The 
difference in activity must therefore be due either to a difference 
in reactivity or to the stereochemistry of a which may be selective 
for some essential cellular nucleophile. 
Both isomers show an affinity for the oestrogen receptor, a 
having approximately tenfold the binding activity of E (ED50 a = 79, 
b = 724 nM). Isomer ~ is by far the most active of the compounds 
tested to date. It has approximately one-seventh the activity of 
oestradiol but is more active than oestrone. 
The difference in binding affinity of the t\<o isomers is 
presumably caused by some steric effect in the receptor binding site. 
The epoxide group of ~ apparently disrupts hydrogen bonding of the 
17S-hydroxyl to a lesser extent that b. 
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The preferred conformation of a in which the methylene group 
of the epoxide is remote from the ring junction (X) has the epoxide 
oxygen anti to the PS-OH. Conversly the equivalent conformation 
of ~ (Y) has the epoxide oxygen syn_ to the l7S-0H. This may explain 
the differential hydrogen bonding and binding observed. (Figure 4.6) 
The compounds showed no selectivity against the ER+ and GH3 cells. 
However, the 16-substituted compound l! also displayed a lack of select-
ivity against GH3 cells, but was selective against ~ICF-7 cells. (Table 3.3, 
page 93) The .epoxides were prepared subsequent to -che testing of the D-
ring and 16-substituted compounds against MCF-7 cells. They have there-
fore not as yet been assayed on the MCF-7 cell line. If their 
receptor binding activity is reflected in their selectivity towards 
oestrogen responsive cells, the l7et-epoxides should show considerable 
activity against the MCF-7 line and possibly tumours with ER+ cells. 
4.2.4 Receptor alkylation 
Both the 16-CL_methylene-y-lactones and the 17-epoxyethano-
compounds display some degree of irreversible binding to the oestrogen 
receptor. This I,as of the same order as reported for t~,e hexestrol-
2,3-oxidopropyl ether [ 101] and also for ORG 4333 [123] 
O~ 
o 
HO 
Hexestrol-2,3-oxidopropyl ether 
Figure 4.6 
HO 
ORG 4333 
which 
OH 
Figure 4.6. 
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Molecular mod e l s shOl,ing preferr ed conformations of 
~a (X) and ~b (Y) in "hich the methylene groups are 
remote from the ring junction. 
189 
was used as a standard in our assays. Both of these latter compounds 
have been designed as potential affinity labels for the oestrogen-
receptor. Previous studies ,have reported almost total irreversible 
binding of nitrogen mustard derj. vati ves of DES and oestrone. [131] 
However, the assay system used, unlike that employed in the present 
study, did not preclude denaturation of the receptor. 
The degree of irreversible binding of the test compounds is 
apparently related to their affinities for the receptor. Saturation 
levels of compounds were used, but their dissociation rates from 
the receptor may differ. Compounds forming relatively st'able 
complexes would thus be more likely to form covalent links. [131] 
In the case of the epoxides the greater degree of irreversible 
binding observed for ~ may be,.a combination of its greater 'affinity 
and its greater reactivity. 
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4.3. Final Comments on Cytotoxicity and Selectivity 
The l7a-epoxyethano-oestrogen 2la, on the basis of its affinity 
HO 
for the oestrogen receptor, appears the most promising as a 
drug selective for breast neoplasms. The compound, together with 
its isomer 2lb, has cytotoxic activity similar to that reported 
for cytotoxic-linked oestrogens presently under investigation. 
This is rather weak compared to the natural products investigated, 
but the reduced electrophilic activity may be an advantage in 
. 
allowing the compound to reach the target cells before non-
specific reactions inactivate it. The potential for selectivity 
of 2la could be better evaluated from its cytoto·xicity towards 
MCF7 cells, and in vivo testing on DMBA-induced mammary 
adenocarcinomas in rats. 
The l6-(a-methylene-y-lactone) substituted oestrogens 
.!! and 20 have lower affinity for the oestrogen receptor than the 
epoxides. .However,~. was selective 1y cytotoxic to\~ards MCF-7 
ce lIs, and this acti vi ty may be improved by separation of the 
isomer with maximum receptor binding activity. 
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The oestrogen-linked alkylating drugs, including those 
studied in this work, form covalent links with the oestrogen 
receptor to Some degree. This property may greatly reduce the 
effectiveness of this class of drug against ER+ tumours which 
are not growth responsive to oestrogens. 
It is probable that more molecules of drug are necessary 
to k ill the target cell than there are receptors present. 
To accumulate to lethal levels therefore, an oestrogen-linked 
drug should dissociate from the receptor to react with essential 
cellular nucleophiles, leaving the receptor free to bind another 
molecule of drug. [149] There is considerable evidence to suggest 
such recycling of oestrogen receptors occurs in the presence of 
oestrogens. [153] Indeed receptor recycling has been proposed as 
a possible mechanism for modulating the target cell response to 
oestrogen. [153] 
Drugs which are believed to act primarily via alkylation of 
DNA, such as the epoxides and nitrogen mustards, may be 
particularly vulnerable to loss of cytotoxic activity by 
irreversible binding to the oestrogen receptor. There is also 
evidence to suggest that the steroid carrier may hinder inter-
action wi th DNA. [106] To overcome this the use of 'spacer' chains 
attaching the alkylating group to the oestrogen nucleus has been 
proposed. [142] It was hoped that this would also reduce covalent 
binding to the receptor, by distancing the alkylating group from 
the binding site, and allowing it to react with cellular 
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nuc1eophi1es. [142] However, affinity chromatographic work has 
demonstrated that a chain of at least 14 atoms attached at the 
7a or 17a positions is necessary to penetrate the receptor. [142] 
Addition of a chain of this length results in significant loss 
of binding activity. [142] 
Attachment of the a1ky1ating moiety to the steroid carrier by 
a labile linkage, is an alternative approach but his type of drug 
will suffer from the disadvantage of non specific hydrolysis of 
the linkage before reaching the target cells. [154] 
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4.4 Mechanisms of Cytotoxicity 
4.4.1 Reaction with thiols 
The D-ring steroidal a-methYlene-o-lactones react rapidly with 
glutathione as observed for the sesquiterpene lac tones elephantopin 
and vernolepin. In comparison the l6-(a-methylene-y-lactone) 
oestrogens, the two l7a-epoxyethano oestrogens and estramustine 
react only extremely slowly. 
As a general trend, ability to react with glutathione, (vernolepin > 
elephantopin > the D-ring a-methylene lactones 
l6a-methylene-y-lactones, l7a-epoxides, estramustine), is reflected 
in the cytotoxicity of the compounds (5 > elephantopin > 4 > 6 > 
vernolepin, l6a-methylene-y-lactones, l7a-epoxides, estramustine). 
The reduced reactivity of the 3-hydroxy derivative ~. relative 
to the acetoxy ~. and the methoxy ~_ may be due to lower solubility or 
to long range electronic effects of the C(3) substituents. Such 
effects have been reported in oestrogens [141] 
All of the alkylating compounds tested reduce thiol levels in 
HeLa S3 cells. The D-ring a-methylene compound! is the most active. 
The l6-(a-methylene-y-lactone) substituted oestrogens, the epoxides and 
estramustine reduce cellular thiols to a lesser degree. Reduction of 
thiols is dose-dependent, for example treatment of cells with 10 ~M 
and 50 ~M concentrations of 4 reduces cellular thiols by 38% and 
64% respectively. The observed depletion-of thiols applies to 
both cell surface and intracellular thiols. It is thus apparent 
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the compounds can penetrate the plasma membrane. The potent 
cytotoxic effect of the D-ring compounds may be due in part to 
increased cellular uptake. This constrasts with the sesquiterpene 
compound vernolepin. Vernolepin is less active than the D-ring 
a-methylene }actones in reducing intracellular thiols, despite 
its greater reactivity with glutathione. Vernolepin also reacts 
more readily Ivith glutathione than elephantopin but is less cytotoxic. 
These observations are believed to be due to the reduced lipophilicity 
of vernolepin relative to elephantopin. [37] 
,Time course experiments with vernolepin demonstrate that 
reduction of thiols reaches an equilibrium with' approximately 61~5 -SH 
remaining one hour or less after addition of drug. Vernolepin,at a 
dose which produces approximately 100% inhibition of growth,does 
not significantly further reduce thiols from this value, even after 
24 hours exposure. The rapidity of thiol depletion is paralleled 
in the cytostatic activity of the D-ring compounds. Growth inhibition 
below control levels is apparent 3 hours after exposure. The 
inhibit~on is only partly reversibl~ by removal of drug and increases 
with longer exposure times. A similar effect has been observed' with 
a sesquiterpene compound. [124] It seems that the effect of the 
D-ring compounds cannot be completely overcome by cellular repair 
mechanisms even after short exposure times. 
Cytotoxicity,of the D;:ring compounds is reduced by the addition of mM 
levels of glutathione to the growth media at the same time as the drug. 
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This effect is presumably due to the formation of glutathione adducts. 
However, the protection afforded by glutathione is not total, even 
in the presence of a thousand~fold excess over the D-ring steroid. 
This may relate to the activity of the thiophenol substituted 
compound ~ (Table 3.1, page 88). 
In spite of the effort put into this work by various laboratories, 
the toxicity of the a-methylene lactones is not considered to be as 
a result of intracellular glutathione depletion, though glutathione 
is involved in a number of cellular functions. Indeed cells may 
remain viable for some time despite almost complete depletion of 
glutathione. [124] However, reduction of glutathione levels does 
potentiate the cytotoxic effects of compounds such as vernolepin and 
elephantopin on treated cells. [124] 
One of the main roles for glutathione is in detoxification, 
by removal of both endogenous toxins and toxic drugs such as the 
alkylating agents. Glutathione reacts with toxic electrophiles 
to form thiother adducts which are actively removed from the cell 
by a translocase system. [155] Depletion of intracellular glutathione 
therefore increases the vulnerability of cells to sulphydryl reactive 
compounds such as the a-methylene lactones. 
Accordingly the effects of the steroidal a-methylene lactones 
on a number of biochemical systems containing thiol species were 
investigated in an attempt to determine their possible modes of 
action. This has further implications since recently it has been 
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suggested that other alkylating agents may owe their antitumour 
properties in part to alkylation of membrane nucleophiles. [156] 
which may be targets rather than, or in addition to DNA. 
4.4.2 [3H}-Thymidineuptakeandincorporation into macromolecules 
Intact membrane sulphydryl groups are required in a variety of 
membrane transport mechanisms. [53] Alkylation or oxidation of these 
groups reduces transport capacity. It is not surprising then that 
sesquiterpene lactone alkylating compounds are repor'~ed to affect 
uptake of a number of molecules by cells in culture. [43] 
The D-ring a-methylene steroidal compound ! is approximately 
tenfold more potent in inhibiting thymidine uptake than elephantopin. 
However, the parent lactone of ~. (compound 7) has acti vi ty in the 
same range as!. This finding suggests that alkylating ability may be 
an unimportant factor. 
Uptake of thymidine by cells in culture is a carrier-mediated 
process. [157] Two distinct transport systems have been identified; 
a high affinity active transport system with a narrow substrate 
specifici ty, and a lbw affinity ul\.i.port system with broad substrate 
specificity. [157] Both of these types of transport system are 
susceptible to changes in the fluidity of the membrane, [158] such 
as might be caused by the addition of lipophilic materials. Consequently 
a series of compmmds were tested to determine if alkylating activity 
was a necessary prerequisite for inhibitory activity. 
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An inhibition of thymidine uptake was observed for the series 
of unrelated compounds such as benzocaine, dexamethazone, oestradiol. 
It is likely therefore that the observed inhibition with the 
a-methylene lactones is a result of a non-specific action on 
membrane fluidity. Inhibition of uridine and amino acid uptake by 
sesquiterpene a-methylene lactones in HeLa S3 cells is reputed to 
occur at relatively high concentrations [43], and this may also be 
due to non-specific membrane effects. 
The effects of compounds on DNA synthesis was evaluated by 
their ability to inhibit incorporation of [3H]-thymidine into acid 
insoluble material. The method used was a modification of that 
described by Plageman. [159] In contrast to the uptake studies; of 
the compounds tested only the a-methylene lactones ! and elephantopin, 
inhibited thymidine incorporation, though this required very high 
doses in accordance with previous work on elephantopin. [43] We 
were unable to detect any effect of the glucocorticoid dexamethazone 
which reportedly inhibits thymidine incorporation [125]though 
dexamethazone did inhibit uptake of thymidine. 
The depression of DNA synthesis reported with a-methylene 
lactone sesquiterpenoids [30,43]. may be due to inhibition of DNA 
pOlymerases 11 and III which are known to be susceptible to thiol 
reag~nts. Inhibition of DNA synthesis is reportedly not caused by 
reduction of thymidine kinase activity. [44] 
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The sesquiterpene lactones do not react directly with DNA, [30,58] 
and it has not been possible to show any reaction of the steroidal 
a-methylene lactones with guanosine in vitro. However, a direct 
action on DNA following metabolic activation has been proposed. [44] 
Certainly damage to the DNA template by high levels of vernolepin 
and elephantopin has been shown. Reduction in the size of DNA 
fragments in HeLa S3 cells has been reported and is attributed to 
excision repair. [44] However, DNA endonuclease activity in Ehrlich 
ascites is depressed by sesquiterpenes, suggesting the reduction 
in DNA fragment size may be due to some other effect. [30] 
The high doses required for inhibition of thymidine incorporation 
into macromolecules could be due to the short assay time used, 
relative to the cytotoxicity studies. On the other hand thiol 
depletion doses occur within this time scale. The rapidity with 
which the a-methylene lactone compounds reduce cellular thiol levels 
suggests that if direct effects on DNA occur they may be later 
events. 
4.4.3 + + Effects on Na /K ATPase 
The activity of Na+/K+ ATPase in HeLa S3 cells in culture was 
assessed by their ability to accumulate the potassium congener 86Rb+. 
This process reaches equilibrium after approximately 3 hours exposure 
to the isotope. That 86Rb+ uptake is mediated by a Na+/K+ pump is 
evident from its abolition by ouabain. 
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Inhibition of 86Rb+ uptake by the compounds tested follows the 
rank order of their cytotoxic potency and their ability to deplete 
cellular thiols. The D-ring a-methylene compound ~ is three-fold 
more active against the transport system than vernolepin which is 
more active than estramustine or the 16a-epoxides 2la and 21b. 1be 
effect on 86Rb+ accumulation is caused predominantly by the 
alkylating activity of the compounds. This is demonstrated by the 
low activity of the D-ring lactone lacking an exocyclic methylene 
function 7. Further the inhibition by vernolepin reaches a maximum 
in less than 30 minutes. Maximum depletion of cellular thiols occurs 
over a similar range. + + Na /K ATPase has a number of essential thiols, 
some of which are located in shielded hydrophobic subunits. [160,161] 
Reaction with these shielded thiols is enhanced in alkylating agents 
which have hydrophobic structures. 
The activity of the nitrogen mustard estramustine is similar to 
that reported for nitrogen mustard itself. [54] + + The Na /K ATPase 
of the PC 6 A mouse plasmacytoma ,cell line is inhibited by the action 
of nitrogen mustard, [54] but the monofunctional analogue (2-chloroethyl) 
dimethylamine is inactive. [54] The difunctional compounds are presumed 
to cross link parts of the enzyme protein. [54] The activity of the 
oestrogen alkylating compounds may therefore indicate a different, 
more specific site of action. For example binding and subsequent 
alkylation of the en:ymic K+ site. This idea may merit further 
investigation since attempts to prepare compounds with this property 
, 
have been made in an effort to probe the active site of the enzyme. [161] 
200 
Within the group of alkylating oestrogens containing a mono-
functional alkylating moiety, differences are apparent. Thus the 
a-methylene lactone compounds i andvernolepin have considerably 
steeper dose/response curves than the epoxides which behave in a 
similar manner to estramustine. 
Inhibition of the isolated enzyme from HeLa S3 cells and of 
commercial enzyme preparations by vernolepin and the D-ring a-
methylene lactone 4 was less easy to demonstrate than 86Rb+ uptake 
inhibition. This difference has also been reported for the effect 
of nitrogen mustard on isolated enzyme preparations from PC 6 A cells. 
[54] Indeed nitrogen mustard produced a 43.4% inhibition of Na+/K+ 
ATPase, but only at millimolar concentrations, five-fold higher than 
that used for vernolepin on the isolated HeLa S3 enzyme. The time-
course of enzyme inhibition of vernolepin is similar to that for 
86 Rb+ uptake by BeLa S3 cells. This further supports the view that 
the effect of these compounds on 86Rb+ accumulation is caused by a 
direct action on the enzyme itself. The a-methylene lactone compounds 
! and vernolepin .exhibited approximately equal inhibition of the 
ouabain sensitive and insensitive enzyme preparations. 
The importance of thiol groups for enzyme activity was confirmed 
by the inhibition observed with the sulphydryl reagent N-ethylmaleimide. 
TIlis compound produced approximately ttvo-fold greater inhibition of 
the enzymes than 4 or vernolepin. 
+ + Interest in the Na /K ATPase system as a possible site of action 
for the anti-tumour alkylating drugs is comparatively recent. [156] 
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Previously it was considered that the number of enzyme molecules was 
too great in comparison to the levels of drug present under 
physiological conditions. [156] Hm,ever, cells of the HeLa line have 
only approximately 106 Na+ /K+ ATPase molecules per cell and comparatively 
small loss of Na+/K+ pumping capacity would alter the flux of other 
2+ 
essential ions, such as Ca , across the cell membrane. [156] 
Consequently cross linking of the enzyme by a number of difunctional 
alkylating compounds, and subsequent imbalance of ions has been 
reported. [54,55] Disruption of ion balance in cells would,be sufficient 
to produce all of the various effects reported for alkylating drugs on 
cells by cascade effects on both protein and DNA synthesis. [57,162,163] 
4.4.4 Effects on oxidative phosphorylation 
TIle D-ring a-methylene compound ~ and elephantopin have no 
significant effect on basal (state 4) respiration in mouse liver 
mitochondria, up to 100 ~M. Pretreatment of the preparation with 
test compounds produced a similar result. ATP-stimulated (state 3) 
respiration is inhibited by both compounds to approximately the same 
degree at 100 ~M, although oestradiol produces a similar inhibition. 
Pretreatment for 2 hours at 4·C marginally increases the inhibitory 
activity of ! and elephantopin. 
TIle results suggest the compounds act as inhibitors of respiration, 
rather than as uncoupling agents. TIle site of inhibition may be the 
ATPase complex of the mitochondria, or some transport mechanism. 
Inhibition of ADP uptake by the mitochondria would produce a similar 
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effect on respiration. [164] As with the effects observed on thymidine 
transport the greater part of the activity appears to be independent 
of the a-methylene lactone function. Respiratory activity in 
mitochondria is sensitive to alterations in the fluidity of the two 
membranes, which have a higher proportion of unsaturated phospholipids 
than other cellular membranes. [165] 
Inhibition of respiration has been reported for the sesquiterpene 
a-methylene lactones both in vivo and in vitro. [59] Some reports 
indicate that .stimulation of state 4 respir~tion occurs with some of 
these compounds, indicating they may act as uncoupling agents. [59] 
The doses used for in vitro testing were of the same level as those 
described in the present experiments. 
4.4.5 Lysosomal membranes 
The effects of the a-methylene lactones elephantopin and the 
a-methylene lactone steroidal compound ~ on cell ultrastructure was 
studied by scanning and transmission electron microscopy. The most 
notable change in the cells, treated with 4, was the disruption of 
the cytoplasm, eventually leading to total disintegration. This 
observation suggested that breakdown of lysosomal membranes may 
occur in cells treated ,·d th :!. and the released enzymes then destroy 
the cells. TIle effects of several compounds on the stability of 
lysosomes prepared from rat liver were therefore studied. 
Compound 4 does indeed destabilise lysosomal membranes, as 
assessed by release of the enzyme aryl sUlphatase. This activity 
of ! is only apparent at the relatively high concentration of 100 ~M; 
no effect was observed at concentrations of 1 ~M or la ~M. This property 
is presumed to be due to the alkylating function since the parent 
lactone 2 has by contrast a slight stabilising effect on the lysosomes. 
By contrast, the sesquiterpenes a-methylene lactones, vernolepin and 
elephantopin, were found to stabilise lysosomal membranes, as has 
been previously reported. [59] The anti-inflammator, actlvity of 
these compounds has been partly ascribed to this property. [59,60] 
Elephantopin and vernolepin inhibit aryl sulphatase activity. 
This effect is believed to be due to alkylation. [59] The inhibition 
observed for the lactone 7 was slightly higher than that for the 
two sesquiterpenes. On the other hand the methylene lactone 4 has 
no inhibitory effect on aryl sUlphatase. 
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4.5. Overview of Mechanisms of Cytotoxicity 
All of the compounds tested perturb membrane functions in 
HeLa S3 cells and in isolated membrane preparations, to some degree. 
Thymidine uptake, oxidative phosphorylation and lysosomal membrane 
stability are all affected. However, the results from these assay 
systems must be interpreted with caution; since at the concentrations 
used the alkylating activity of the compounds may be masked by their 
intrinsic hydrophobici ty, which also perturbs membrane function. 
This is apparently not the case with the inhibition of Na+/K+ 
ATPase of HeLa S3 cells observed for the a-methylene lactone 
compounds. In this system the inhibition of the membrane ion pump 
is predominantly due to alkylating activity, for vernolepin and the 
steroidal a-methylene lactone compound ~at least. TIle relatively 
low activity of the epoxide 2la and nitrogen mustard comp0und 
estramustine may indicate they have a different site of action. 
Alkylating agents of all classes have been found to inhibit a 
variety of cellular functions. To date it has not been possible to 
determine unequivocally which is their primary site of action, if 
indeed there is only one. However, continued investigation of the 
mode of action of the alkylating drugs may still prove productive 
in contributing to design of improved drugs. 
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